CN115586335A

CN115586335A - Polymerase-antibody combination for rapid immunohistochemistry in melanoma surgery

Info

Publication number: CN115586335A
Application number: CN202211375416.2A
Authority: CN
Inventors: 伍进; 赵松庆; 王健夫; 陈硕
Original assignee: Guizhou Meixinda Medical Technology Co ltd
Current assignee: Guizhou Meixinda Medical Technology Co ltd
Priority date: 2021-11-04
Filing date: 2022-11-04
Publication date: 2023-01-10
Anticipated expiration: 2042-11-04
Also published as: CN115840047B; CN115840047A; CN115586335B

Abstract

The invention relates to a polymerase-antibody combination for rapid immunohistochemistry in melanoma surgery. The present application relates to polymerase/antibody conjugates and combinations thereof for rapid immunohistochemistry in oncology, kits comprising the polymerase/antibody conjugates or combinations thereof, and their use in the diagnosis of cancer, such as melanoma.

Description

Polymerase-antibody combination for rapid immunohistochemistry in melanoma surgery

Technical Field

The present invention relates generally to rapid identification and tumor typing of tumors, and more particularly to a polymerase/antibody conjugate and a combination thereof for rapid identification and tumor typing of intraoperative tumors such as brain tumors, lymphomas, melanomas, and metastatic cancers and determination of margin-negativity of surgical resection of tumor tissue, a kit comprising the polymerase/antibody conjugate and/or the combination thereof, a method, and applications thereof.

Background

Importance of rapid and accurate identification of tumors for optimal brain tumor resection during surgery

The number of primary brain tumors that occur annually worldwide is approximately 250,000. Brain tumors are graded from low (I) to high (IV) malignancy according to their histiocytic morphology and growth rate. Surgical resection of brain tumors is the first option for treatment and is generally the only treatment for low-grade brain tumors. Removal of brain tumors reduces intracranial pressure to relieve symptoms and reduce the volume of tumor mass that needs to be treated by subsequent radiation therapy or chemotherapy. It is generally desirable to maximize the effort to eliminate invasive brain tumors during surgery, otherwise residual invasive cancer cells continue to grow leading to tumor recurrence, thereby reducing the overall survival of the patient. However, when tumors infiltrate the surrounding delicate, functionally normal brain tissue, complete clearance of the brain tumor becomes nearly impossible ^[1] . Currently, preoperative imaging localization and intraoperative precise identification of tumors are essential options to promote optimal tumor resection ^[2] . Most non-invasive brain cine scans can only accurately locate brain tumor masses at millimeter levels. There is still a need for differential cancer diagnosis at the tissue cell level by tissue morphology during surgery to allow the surgeon to make an important decision whether to excise or not. This is particularly true for malignant brain cancers. Hematoxylin and eosin tissue and cell staining on intraoperative cryosections with a hundred year history is still necessary today and is currently the main method for the differential diagnosis and marginal determination of intraoperative brain tumors.

Inherent quality defects of intraoperative cryosection hematoxylin and eosin staining

The method of identifying tumors by staining slides with hematoxylin and eosin on frozen sections can only rely on the pathologist to visually inspect the morphology of the tissue cytology under a microscope. Thus, the quality of hematoxylin and eosin staining of cryo-sectioned tissues has been a determinant of intraoperative cryo-sectionThe main limiting factor for the accuracy of the diagnosis of cancer. In essence, the frozen section hematoxylin and eosin staining technique has two inherent problems that are difficult to overcome. The first problem is the defects caused by freezing. The soft nature of brain tissue and the high moisture content of the tissue freezing process introduces ice crystals into the tissue, resulting in the formation of freezing artifacts throughout the tissue, distorting cell morphology. For example, frozen tissue often produces irregularities in the nuclear contour of oligodendrogliomas, making it appear similar to astrocytomas and thus difficult to distinguish. A second inherent problem with cryo-section hematoxylin and eosin staining is that due to their non-specific chemical staining properties, histological structures based on molecular level differences cannot be resolved. These inherent drawbacks pose significant challenges and burdens on clinical pathologists who are diagnostic based on frozen-section tissue morphology, who can only rely on microscopic histological morphology to identify and differentiate cancerous tissues in a short period of time. For example, in cryo-section hematoxylin and eosin staining, it is very difficult to distinguish between meningiomas, peripheral nerve sheath tumors, and spindle cell proliferation. Differentiating between reactive gliosis and low grade glioma is one of the most difficult differential diagnostic challenges in surgical neuropathology ^[3] . Brain surgery requires clear differentiation of metastatic cancers, meningiomas, medulloblastomas, melanomas, gliomas with IDH 1R 132H mutations, astrocytomas, secondary glioblastoma, etc., and chemical staining of cryosections with hematoxylin and eosin alone is not sufficient for rapid identification of these brain tumor tissue types.

Efforts to improve diagnosis in brain tumor surgery

1) Coherent Raman scattering microscopy can amplify spontaneous Raman signals by 10,000 times, and can perform real-time histological imaging without tissue processing, slicing and staining ^[4] . This brain tissue imaging technique demonstrated some consistency with cryo-section hematoxylin and eosin staining results ^[4] . However, this technique has limited specificity and is not universally applicable.

2) Rapid evaporative ionization mass spectrometry is an emerging technology, canNear real-time characterization of in vivo human tissue is performed by analyzing aerosols released during electrosurgical dissection. The instrument is still very expensive. Whether the performance of the instrument can exceed the hematoxylin and eosin staining of the frozen section or not is yet to be observed ^[5] 。

3) Confocal microscopy for real-time histopathological imaging of brain tumors is another in vivo imaging technique that relies on tumor-specific fluorescent contrast agents. Its role in intraoperative interpretation remains to be assessed ^[6] 。

4) Rapid immunohistochemistry using a Polyhorseradish peroxidase (PolyHRP) -labeled anti-cytokeratin secondary antibody allowed the achievement of sentinel lymph node Immunohistochemistry (IHC) staining within 20 minutes ^[7] . Dako (California ) introduced the rapid immunohistochemical staining kit EnVision, which allowed staining of frozen sections within about 20 minutes at 37 ℃. The two-step staining method using a labeled secondary antibody adds a one-step staining procedure and requires more time than the direct method. However, according to the feedback information applied in the Mohs clinic, the actual process takes about 45 minutes.

5) For low cell invasive gliomas, intraoperative cryo-section hematoxylin and eosin staining were difficult to identify due to non-specificity of staining and low color difference. Rapid and sensitive genotyping methods have been developed for detecting somatic cell mononucleotide isocitrate dehydrogenase 1 (IDH 1), detecting IDH1 mutations by real-time PCR, and detecting metabolites of 2-hydroxyglutarate, mutant IDH by mass spectrometry. The method showed results within 60 minutes.

Although the technological advances described above have facilitated intraoperative evaluation of brain tumors from different perspectives, cryo-section hematoxylin and eosin staining procedures are still being compared as a benchmark to show limited improvement in some cases of difficult hematoxylin and eosin staining.

Research and application of polymerase antibody conjugate in prior art

In order to obtain direct coupling of the polymerase to the antibody and thus greater amplification of the chromogenic signal, a number of specific methods for preparing and coupling the polymerase to the antibody have been described in a number of earlier inventions. For example, patent CN1300942a describes various preparation methods, one of which uses focusing is immunoassay in solution, and the other is immunohistochemical staining on conventional paraffin-embedded tissue sections, but the staining incubation time alone exceeds 60 minutes, and the staining speed is too slow to be applied to intraoperative detection. European patent EP0175560A2 describes a method for preparing an antibody coupled with various enzymes to form a polymerase/antibody for quantitative determination of antibody binding to antigen. The measurement of the immunological binding reaction described in this patent is performed unhindered in solution. Immunohistochemical staining of biological tissues is distinct from immune reactions in solution, antibodies and antibody conjugates face complex and irregular spatial hindrance of tissues, many antibodies can easily react with antigen binding in solution, but cannot react with antigen binding within tissues, and thus immune reactions in solution cannot be easily and directly generalized to immunohistochemical staining of biological tissues, where the technological spread is not obvious. CN 1945333A discloses a reagent for rapid immunohistochemical detection of breast cancer lymph node metastasis and a detection method using the reagent, wherein multiple antibodies directly labeled to distinguish metastatic cancer cells from lymph node inherent cells are mixed into the reagent, and the reagent specifically stains the metastatic cancer cells in the lymph node through one-step reaction. The technology is characterized in that the density of antigens correspondingly positioned in tissues is increased by mixing and coupling the polymerase and a plurality of positive breast cancer metastasis antibodies, so that the amplification gain of a polymerase signal is increased, but the method still needs 15-20 minutes to realize the intraoperative diagnosis of breast cancer lymph node metastasis.

Thus, there remains a need for more accurate and reliable methods for more rapid identification for the detection of samples from brain tumor tissue. (1) In order to significantly improve the diagnostic accuracy in brain tumor surgery, the staining signal must be specifically enhanced on histological features at a specific molecular level; (2) All of these testing procedures must be completed in less than 10-15 minutes to meet the time constraints of intraoperative testing; (3) It is necessary to have multiple reagents with molecular specific staining to form antibody combinations, and the results of these antibody combination staining can be used to identify multiple tumor types more accurately.

In view of the above, the present invention satisfies the above-mentioned needs by optimizing the distribution and random diversity of molecular weights of direct polymerase-antibody conjugation to achieve highly sensitive and high-speed staining of a single antigen and forming a diagnostic combination necessary in tumor surgery with a plurality of direct conjugates of polymerase-antibody with antibodies, which are associated with brain tumors, lymphomas, melanomas, metastatic cancers, and the like, and achieves immunohistochemical differential diagnosis in brain tumor surgery, which has been difficult to achieve in the past.

Disclosure of Invention

The invention adopts the polymerase to directly couple the antibody, and then the polymerase/antibody conjugates of a plurality of specific antibodies form a matched antibody combination for quickly identifying the tumor, and the quick and accurate immunohistochemical staining on a frozen tissue slice is implemented in the tumor surgery.

In one aspect, the invention provides a polymerase/antibody conjugate of a polymerase and an antibody. In the polymerase/antibody conjugates of the present invention, each polymerase antibody conjugate may comprise: (i) One or more polymerases, (ii) an antibody that recognizes a target analyte.

In some embodiments according to any of the embodiments above, the polymerase/antibody conjugate comprises a plurality of polymerases. In some embodiments, the polymerase/antibody conjugate comprises a plurality of enzyme molecules, each polymerase/antibody conjugate comprising a different number of enzyme molecules. In some embodiments, the polymerase/antibody conjugate comprises a plurality of polymerases, wherein the number of enzyme molecules of each polymerase among the plurality of polymerases can be the same or different. In some embodiments, the polymerase/antibody conjugate comprises a plurality of polymerases, wherein the combinatorial structure of the plurality of polymerases can vary.

In some embodiments according to any of the above embodiments, a polymerase/antibody conjugate of the invention can comprise a plurality of polymerases and antibodies, wherein each polymerase comprises a different number of enzyme molecules, and wherein the molecular weights of the conjugates form a polydisperse distribution characterized by a molecular weight of about 400kDa to about 2,000kda of each polymerase/antibody conjugate. The polydisperse distribution means that the number of polymerase/antibody conjugates in each partition within the molecular weight range as defined above is not zero. For example, between 400 and 600kDa it accounts for about 2 to 8%, e.g.4%, 5%, 6%, 7% or 8%, preferably 4% to 6% of the total molecular weight range; between 600-800kDa about 5-10%, e.g. 6%, 7%, 8%, 9% or 10%, preferably 7-9%; 6-13%, e.g. 7%, 8%, 9%, 10%, 11% or 12%, preferably 9-11% between 800-1000 kDa; 7-14% between 1000-1200kDa, such as 8%, 9%, 10%, 11%, 12%, 13% or 14%, preferably 9% -12%; 9-16% between 1200-1400kDa, e.g. 9%, 10%, 11%, 12%, 13%, 14%, 15% or 16%, preferably 11-13%; 10-16% between 1400-1600kDa, e.g. 10%, 11%, 12%, 13%, 14%, 15% or 16%, preferably 12-14%; between 1600 and 2000kDa 12-18%, e.g. 12%, 13%, 14%, 15%, 16%, 17% or 18%, preferably 13% -15%. Further, in more specific examples, for example, in preferred exemplary polymerase/antibody conjugates (e.g., as used in the examples), the number of molecules between 400 and 600kDa is about 4% -6% of the number of molecules in the entire molecular weight range; between 600-800kDa and about 7% -9%; between 800-1000kDa and about 9% -11%; between 1000-1200kDa and about 10% -12%; between 1200 and 1400kDa, about 11% -13%; between 1400 and 1600kDa, about 12% -14%; between 1600 and 2000kDa, about 13% -15%.

More specifically, the polymerase/antibody conjugate of the invention may have a molecular weight of 300kDa to about 10,000kDa, preferably 400kDa to about 10,000kDa, 400kDa to about 5,000kDa, 500kDa to about 5,000kDa or 750kDa to about 5,000kDa, with different molecular weights in each interval within this range, and the molecular weight of the conjugate forming a polydisperse distribution as described above.

In one embodiment, the three-dimensional structure of the polymerase/antibody conjugate is randomly distributed over various molecular weight ranges, e.g., a polymerase/antibody conjugate comprising randomly different three-dimensional structures within the range of 400kDa to about 8,00kda; polymerase/antibody conjugates comprising another type of random different three-dimensional structure within the interval of 800kDa to about 1,200kda; polymerase/antibody conjugates comprising other types of random different three-dimensional structures within the interval of 1,200kda to about 1,600kda; other types of polymerase/antibody conjugates comprising randomly different three-dimensional structures are included in the interval of 1,600kda to about 2,000kda, wherein the three-dimensional structures of the polymerase/antibody conjugates in the above four intervals may be different.

In some embodiments according to any of the embodiments described above, a polymerase/antibody conjugate of the invention can comprise a plurality of polymerases, and the total number of polymerases in each polymerase/antibody conjugate comprises a varying number of enzyme molecules, e.g., can comprise 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 50, 60, 70, 80, 90, 100, 120, 140, 150, 160, 180, 200, 220, 240, and/or 250 enzyme molecules, or one or more of the aforementioned numbers.

In some embodiments according to any of the above embodiments, the molecular weight distribution of the polymerase/antibody conjugate of the invention is heterogeneous among molecular weight regions and the three-dimensional structure is random in composition. For example, the three-dimensional structure of the polymerase/antibody conjugates of the invention is random and varies from one molecular weight region to another. In some embodiments according to any of the embodiments above, the polymerase/antibody conjugate of the invention comprises a plurality of enzyme molecules or polymerases, wherein the plurality of enzyme molecules or polymerases can comprise the same or different enzyme types. For example, all enzyme molecules or polymerases in a polymerase/antibody conjugate of the invention can be horseradish peroxidase.

In some embodiments according to any of the embodiments described above, the enzyme molecule of the polymerase used in the polymerase/antibody conjugate of the present invention may comprise horseradish peroxidase (HRP), β -D-galactosidase, alkaline phosphatase, superoxide dismutase, luciferase, lactate dehydrogenase, galactose oxidase, or the like.

In some embodiments, the polymerase/antibody conjugates of the invention can be formed by covalently linking a polymerase to an antibody.

In some embodiments according to any of the embodiments described above, the polymerase/antibody conjugate of the invention may comprise a primary antibody (i.e., a primary antibody). In some embodiments, the primary antibody can comprise a full-length antibody, a monoclonal antibody, a polyclonal antibody, a chimeric antibody, a humanized antibody, a human antibody, or an antibody fusion protein, or an antigen-binding fragment thereof. In some embodiments according to any of the embodiments above, the primary antibody may comprise an antibody or antigen binding fragment thereof that targets the antigen of interest of the invention and its associated diseases such as cancer. In some embodiments according to any of the embodiments above, the primary antibody may be selected from an antibody or antigen binding fragment thereof targeting the antigen of interest of the invention and its associated disease, such as cancer. In further embodiments, the cancer comprises or is selected from brain tumors, such as brain gliomas, meningiomas, medulloblastomas, ependymomas, schwannoma, intracranial neuroepithelial tumors, chordoma; epithelioid sarcoma; lymphoma; small cell carcinoma; a synovial tumor; neuroendocrine cell tumors including olfactory cell tumors, medulloblastoma, neuroblastoma, pituitary adenoma; melanoma; lymphoma; metastatic tumors; oligodendroglioma, IDH1 mutant tumor, astrocytoma, schwann cell tumor, choroid plexus neuroma, papillary tumor, spindle tumor, atypical teratoid/neoplasia-like. In still further embodiments according to any of the embodiments above, the primary antibody or antigen-binding fragment may comprise one or more, such as any two, three, four, five, six, seven or eight, of anti-Pan-CK, anti-GFAP, anti-EMA, anti-synaptoprotein (synaptophysin), anti-CD 45, anti-CD 34, anti-Mart-1 and anti-Sox-10 antibodies or antigen-binding fragments thereof. In still further embodiments according to any of the embodiments above, the primary antibody or antigen-binding fragment may comprise one or more of anti-Pan-CK, anti-GFAP, anti-EMA, anti-synaptophysin, anti-CD 45, anti-Mart-1, and anti-Sox-10 antibodies or antigen-binding fragments thereof, e.g., any two, three, four, five, six, seven, or eight thereof.

In some embodiments according to any of the embodiments described above, the polymerase molecules used in the polymerase/antibody conjugates of the invention can be covalently linked via a cross-linking agent. In some embodiments, the enzyme molecules of the polymerase can be directly covalently linked. In some embodiments, the enzyme molecules of the polymerase are covalently linked in a linear fashion. In some embodiments, the enzyme molecules of the polymerase are covalently linked in a branched fashion. In some embodiments, the enzyme molecules of the polymerase are covalently linked in a mixed linear and branched fashion.

In some embodiments according to any of the embodiments described above, the polymerase used in the polymerase/antibody conjugate of the invention can have a molecular weight of about 300kDa to about 5 megadaltons (MDa). In some embodiments, the polymerase has a molecular weight of at least about 500 kDa. In some embodiments, the polymerase has a molecular weight of less than or about 5 MDa. In some embodiments, the polymerase has a molecular weight of at least about 750 kDa. In some embodiments, the polymerase has a molecular weight of at least about 1,2, 3, or 4 MDa.

In some embodiments according to any of the embodiments above, the polymerase is formed first before being conjugated to the antibody.

In another aspect, the invention provides a combination of polymerase/antibody conjugates comprising a plurality of polymerase/antibody conjugates as described above, e.g., two, three, four, five, six, seven, or eight different polymerase/antibody conjugates. Preferably, the combination of polymerase/antibody conjugates of the invention comprises or consists of a polymerase/antibody conjugate of anti-Pan-CK, anti-GFAP, anti-EMA and/or anti-CD 34, anti-synaptophysin (Synatophysin), anti-CD 45, and anti-Mart-1 and/or anti-Sox-10 antibodies, or antigen binding fragments thereof. More preferably, the combination of polymerase/antibody conjugates of the invention comprises an anti-Mart-1 and/or anti-Sox-10 antibody, and at least one (e.g. two, three, four, five and six) of the following antibodies: a polymerase/antibody conjugate of or consisting of anti-Pan-CK, anti-GFAP, anti-EMA, anti-CD 34, anti-synaptophysin, and anti-CD 45 antibodies or antigen-binding fragments thereof. In the combination of polymerase/antibody conjugates of the invention, each polymerase/antibody conjugate may comprise: (i) One or more polymerases, (ii) an antibody that recognizes the analyte of interest.

In some embodiments according to any of the embodiments described above, each polymerase/antibody conjugate in a polymerase/antibody conjugate combination of the invention can comprise a plurality of enzyme molecules or a plurality of polymerases, wherein the plurality of enzyme molecules or the plurality of polymerases can comprise the same or different enzyme types, e.g., all enzyme molecules or polymerases in a polymerase/antibody conjugate of the invention can be horseradish peroxidase.

In some embodiments according to any of the embodiments above, in the polymerase/antibody conjugate combination of the invention, the enzyme molecule of the polymerase may comprise horseradish peroxidase, β -D-galactosidase, alkaline phosphatase, superoxide dismutase, luciferase, lactate dehydrogenase, galactose oxidase, and the like.

In some embodiments according to any of the embodiments above, each polymerase/antibody conjugate in the polymerase/antibody conjugate combination of the invention comprises a primary antibody and a polymerase, wherein the primary antibody may comprise a full-length antibody, a monoclonal antibody, a polyclonal antibody, a chimeric antibody, a humanized antibody, a human antibody or antibody fusion protein, or an antigen-binding fragment.

In some embodiments according to any of the above embodiments, each polymerase/antibody conjugate in a polymerase/antibody conjugate combination of the invention comprises a primary antibody and a polymerase, wherein the primary antibody in each polymerase/antibody conjugate comprises an antibody to a different antigen.

In some embodiments according to any of the above embodiments, each polymerase/antibody conjugate in the polymerase/antibody conjugate combinations of the invention comprises a primary antibody, which may include or be selected from an antibody or antigen-binding fragment targeting a different antigen of interest and its associated disease, such as cancer, and a polymerase. In a further embodiment, the cancer comprises or is selected from: brain tumors, such as brain gliomas, oligodendrogliomas, IDH1 mutant tumors, astrocytic tumors, schwann cell tumors, choroid plexus neuroma, papillary tumors, spindle tumors, atypical teratoid/teratoid tumors, meningiomas, medulloblastomas, ependymomas, schwann neuroepitheliomas, chordomas; epithelioid sarcoma; lymphoma; small cell carcinoma; a synovial tumor; neuroendocrine cell tumors including olfactory cell tumors, medulloblastoma, neuroblastoma, pituitary adenoma; melanoma; lymphoma; metastatic tumors, and the like.

In still further embodiments according to any of the above combination embodiments, the primary antibody or antigen-binding fragment thereof may comprise or be selected from two or more, such as three, four, five, six, seven or eight antibodies or antigen-binding fragments thereof: anti-Pan-CK, anti-GFAP, anti-EMA, anti-synaptoprotein (Synatophysin), anti-CD 34, anti-CD 45, anti-Mart-1, and anti-Sox-10 antibodies or antigen-binding fragments.

In some embodiments according to any of the above combination embodiments, in the combination of polymerase/antibody conjugates of the invention, each polymerase/antibody conjugate comprises a primary antibody and a polymerase, wherein the primary antibody may be an antibody directed against a different antigen. Preferably, for example, the combination of polymerase/antibody conjugates of the invention may comprise an anti-Mart-1 and/or anti-Sox-10 antibody and at least one (e.g., two, three, four, five, and six) antibody selected from the group consisting of: anti-Pan-CK, anti-GFAP, anti-EMA, anti-synapsin (Synatophysin), anti-CD 34, anti-CD 45.

In some embodiments according to any of the embodiments above, in the combination of polymerase/antibody conjugates of the invention, each polymerase/antibody conjugate comprises a primary antibody and a polymerase, wherein each polymerase/antibody conjugate comprises a primary antibody or antigen-binding fragment thereof directed against a different antigen. Preferably, the primary antibody is selected from two or more, for example any three, four, five, six, seven or eight, of anti-Pan-CK, anti-GFAP, anti-EMA, anti-synaptophysin, anti-CD 34, anti-CD 45, anti-Mart-1 and anti-Sox-10 antibodies or antigen-binding fragments thereof.

In some embodiments according to any of the embodiments described above, the polymerase molecules used in the polymerase/antibody conjugate combination of the invention can be covalently linked via a crosslinking reagent. In some embodiments, the enzyme molecules of the polymerase can be directly covalently linked. In some embodiments, the enzyme molecules of the polymerase are covalently linked in a linear fashion. In some embodiments, the enzyme molecules of the polymerase are covalently linked in a branched fashion. In some embodiments, the enzyme molecules of the polymerase are covalently linked in a mixed linear and branched fashion.

In some embodiments according to any of the embodiments above, the polymerase population comprising a plurality of polymerases in the polymerase/antibody conjugate combination of the invention comprises a size distribution of polymerases characterized by the number of enzyme molecules per polymerase. In some embodiments, a population of polymerases comprising a plurality of polymerases comprises a polydisperse distribution of polymerases characterized by a structure of the polymerase.

In a further embodiment according to any of the embodiments above, the size distribution of the molecular weight of the population of polymerases comprising a plurality of polymerases in the combination of polymerase/antibody conjugates of the invention is heterogeneous and random. In some embodiments, the population of polymerases comprising the plurality of polymerases exhibits a random polydisperse distribution of molecular weights ranging from about 300kDa to about 5000kDa, with different molecular weights in each region.

In some embodiments according to any of the embodiments described above, the polymerase used in the combination of polymerase/antibody conjugates of the invention can have a molecular weight of about 300kDa to about 5 megadaltons (MDa). In some embodiments, the polymerase has a molecular weight of at least about 500 kDa. In some embodiments, the polymerase has a molecular weight of less than or about 5 MDa. In some embodiments, the polymerase has a molecular weight of at least about 750 kDa. In some embodiments, the polymerase has a molecular weight of at least about 1,2, 3, or 4 MDa.

In some embodiments, the polymerase is first formed before being conjugated to the antibody.

In another aspect of the present invention, the present invention provides a kit comprising a polymerase/antibody conjugate or a combination of polymerase/antibody conjugates of the present invention as described above, said kit comprising a polymerase/antibody conjugate or a combination of polymerase/antibody conjugates as described above, wherein each polymerase/antibody conjugate in said polymerase/antibody conjugate or combination of polymerase/antibody conjugates as described above may comprise a plurality of primary antibodies, preferably said plurality of primary antibodies may be antibodies directed against different antigens.

In further embodiments according to any of the embodiments above, the plurality of primary antibodies may comprise two or more, such as three, four, five, six, seven or eight antibodies or antigen-binding fragments, of: anti-Pan-CK, anti-GFAP, anti-EMA, anti-synaptoprotein (Synatophysin), anti-CD 34, anti-CD 45, anti-Mart-1, and anti-Sox-10 antibodies or antigen-binding fragments thereof.

In a further embodiment according to any of the embodiments above, the plurality of primary antibodies may be selected from two or more, such as three, four, five, six, seven or eight antibodies or antigen-binding fragments thereof: anti-Pan-CK, anti-GFAP, anti-EMA, anti-synaptoprotein (Synatophysin), anti-CD 34, anti-CD 45, anti-Mart-1, and anti-Sox-10 antibodies or antigen-binding fragments.

The kit of the invention comprises a polymerase/antibody conjugate as described above, or a combination thereof, and instructions for use, wherein each of the plurality of polymerase/antibody conjugates can comprise: (i) One or more polymerases, (ii) an antibody that recognizes a target analyte. For example, a kit may comprise two or more, such as three, four, five, six, seven or eight, antibodies or polymerase/antibody conjugates of antigen-binding fragments: anti-Pan-CK, anti-GFAP, anti-EMA, anti-synaptoprotein (Synatophysin), anti-CD 34, anti-CD 45, anti-Mart-1, and anti-Sox-10 antibodies or antigen-binding fragments thereof.

In some embodiments, the kits of the invention further comprise a substrate for the polymerase.

In yet another aspect of the invention, the invention provides a method for detecting a target analyte in a tissue sample, comprising:

contacting a tissue sample comprising a target analyte with a polymerase/antibody conjugate comprising a plurality of enzyme molecules and an antibody that recognizes the target analyte to form a complex comprising the target analyte and the polymerase/antibody conjugate; substantially removing the polymerase/antibody conjugate that does not form a complex; and contacting the tissue with a substrate for a plurality of enzyme molecules, thereby detecting the target analyte. In some embodiments, the tissue is frozen tissue. In some embodiments the tissue sample is a continuous paraffin or a continuous frozen tissue section.

In some embodiments according to any of the above embodiments of the invention, the method further comprises a blocking step followed by the steps of: contacting a tissue comprising a target analyte with a polymerase/antibody conjugate comprising a plurality of enzyme molecules and an antibody that recognizes the target analyte to form a complex comprising the target analyte and the polymerase/antibody conjugate; wherein the sealing step comprises contacting the tissue with a sealing agent. In some embodiments, the tissue is frozen tissue. In some embodiments, the blocking agent comprises skim milk, BSA, casein, or animal serum.

In a further aspect of the invention, the invention provides the use of a polymerase/antibody conjugate or a combination of polymerase/antibody conjugates as described above in the preparation of a reagent or a combination of reagents or a kit for detecting a target analyte in a tissue.

In a further aspect of the invention, the invention provides the use of a polymerase/antibody conjugate or a combination of polymerase/antibody conjugates as described above in the preparation of a reagent or combination of reagents or kit for identifying the type or grade of cancer (e.g. of an intra-operative sample) or determining the margin-negative of surgical resection of tumour tissue.

In a further aspect of the invention, the invention provides the use of a polymerase/antibody conjugate or a combination of polymerase/antibody conjugates as described above in the preparation of a reagent or combination of reagents or kit for the identification or diagnosis of melanoma (e.g. of an intra-operative sample).

In a further aspect of the invention, the invention provides the use of a polymerase/antibody conjugate or a combination of polymerase/antibody conjugates as described above in the preparation of a reagent or combination of reagents or kit for the identification or diagnosis of metastatic cancer (e.g. of an intra-operative sample).

In a further aspect of the invention, the invention provides the use of a polymerase/antibody conjugate or a combination of polymerase/antibody conjugates as described above for the preparation of a reagent or a combination of reagents or a kit for the identification and/or diagnosis of a brain tumor (e.g. of an intraoperative sample), such as glioma, meningioma, medulloblastoma, lymphoma and the like.

Drawings

The features of the invention are set forth with particularity in the appended claims. The features and advantages of the present invention will be better understood by those skilled in the art by reference to the following detailed description of illustrative embodiments and the accompanying drawings, in which:

FIG. 1 shows the results of 10 minute rapid staining of frozen prostate cancer sections using a preferred exemplary polyperoxidase/Pan-CK antibody conjugate of the present invention (20X). Prostate cancer epithelial cells were positive (as indicated by the arrow).

FIG. 2 shows the results of 10 min rapid staining of brain glioma cryosections (20X) using a preferred exemplary polyperoxidase/GFAP antibody conjugate of the present invention. Brain glioma regions stained positively (as indicated by the arrows).

FIG. 3 shows the results of 10 min rapid staining of frozen kidney tissue sections (20X) using a preferred exemplary polyperoxidase/EMA antibody conjugate of the present invention. Epithelial cells from kidney tissue stained positively (as indicated by the arrow).

FIG. 4 shows the results of 10 min rapid staining of liver neuroendocrine tumor tissue frozen sections using a preferred exemplary polyperoxidase/synaptin antibody conjugate of the present invention (20X). Synaptoprotein-presenting staining of neuroendocrine tumor tissue (as indicated by arrows).

FIG. 5 shows representative results (20X) of 10 minute rapid staining of tonsil cryosections using a preferred exemplary polyperoxidase/CD 45 antibody conjugate of the present invention. Lymphocytes of the tonsils stained positively for CD45 (as indicated by the arrow).

Fig. 6 shows representative results (20X) of 10 minute rapid staining of melanoma cryosections using a preferred exemplary polyperoxidase/Mart 1 antibody conjugate of the present invention. Melanoma cells stained positively for Mart-1 (as indicated by the arrow).

Figure 7 shows representative results (20X) of rapid staining of melanoma cryosections using a preferred exemplary polyperoxidase/Sox 10 antibody conjugate of the present invention. Melanoma cells stained positively for Sox10 (as indicated by the arrow)

Fig. 8A to 8H show the results of rapid staining of frozen serial sections of low-grade gliomas using combinations of exemplary polyperoxidase/antibody conjugates of the present invention (10X). 8A, a low-grade glioma is negative according to a dyeing result of the polyperoxidase/Pan-CK antibody conjugate; 8B polyperoxidase/anti-GFAP antibody conjugate, the low-grade glioma is positive; 8C, dyeing and staining the polyperoxidase/synapsin antibody conjugate, wherein the low-grade glioma is weakly positive; 8D, the result of the polyperoxidase/EMA antibody conjugate staining is that the low-grade glioma is negative; 8E, the result of the staining of the polyperoxidase/CD 45 antibody conjugate shows that the low-grade glioma is negative; 8F, dyeing and staining the polyperoxidase/Mart 1 antibody conjugate, wherein the low-grade glioma is negative; 8G, the polyperoxidase/Sox 10 antibody conjugate is dyed and dyed, and the low-grade glioma is negative; 8H.H and E staining control.

Fig. 9A to 9H show the results of rapid staining of high grade glioma frozen serial sections using a combination of exemplary polyperoxidase/antibody conjugates of the present invention (10X). 9A, a polyperoxidase/Pan-CK antibody conjugate staining result shows that the high-grade glioma is negative; 9B polyperoxidase/GFAP antibody conjugate staining result, high-grade glioma is positive; 9C, dyeing and staining the polyperoxidase/EMA antibody conjugate, wherein the high-grade glioma is negative; 9D, the polyperoxidase/synapsin antibody conjugate is dyed and dyed, and the high-grade glioma is negative; 9E, the polyperoxidase/CD 45 antibody conjugate is dyed and dyed, and the high-grade glioma is negative; 9F, dyeing results of the polyperoxidase/Mart 1 antibody conjugate show that the high-grade glioma is negative; 9G, the polyperoxidase/Sox 10 antibody conjugate is dyed and dyed, and the high-grade glioma is negative; 9H.H and E staining control.

Fig. 10A to 10H show the results of rapid staining of frozen serial sections of metastatic cancer using a combination of exemplary polyperoxidase/antibody conjugates of the present invention. 10A, staining by a polyperoxidase/Pan-CK antibody conjugate, and enabling metastatic cancer cells to be positive; 10B, dyeing by using a polyperoxidase/EMA antibody conjugate, and determining that metastatic cancer is weakly positive; 10C, the result of the polyperoxidase/GFAP antibody conjugate staining shows that the metastatic cancer is negative; polyperoxidase/synapsin antibody conjugate staining, and the metastatic cancer is negative; 10E, polyperoxidase/CD 45 antibody conjugate staining, and the metastatic cancer is negative; 10F, dyeing the polyperoxidase/Mart 1 antibody conjugate, wherein the metastatic cancer is negative; 10G, dyeing by using the polyperoxidase/Sox 10 antibody conjugate, wherein the metastatic cancer is negative; 10H.H &E staining control.

Fig. 11A to 11H show the results of rapid staining of frozen serial sections of malignant melanoma (10X) using a combination of preferred exemplary polyperoxidase/antibody conjugates of the present invention. Staining with polyperoxidase/Pan-CK antibody conjugate, and determining that melanoma cells are negative; staining with polyperoxidase/EMA antibody conjugate, and determining that melanoma is negative; 11C, the result of the staining of the polyperoxidase/GFAP antibody conjugate shows that melanoma is negative; polyperoxidase/synapsin antibody conjugate staining, melanoma negative; 11E, polyperoxidase/CD 45 antibody conjugate staining, melanoma is negative; 11 F.polyperoxidase/Mart 1 antibody conjugate staining, melanoma positive (cytoplasmic); polyperoxidase/Sox 10 antibody conjugate staining, melanoma positive (nuclei); 11h. H and e staining control.

Fig. 12A to 12H show the results of rapid staining of paraffin serial sections of malignant melanoma using a combination of preferred exemplary polyperoxidase/antibody conjugates of the present invention (20X). 12A, staining by a polyperoxidase/Pan-CK antibody conjugate, and determining that melanoma cells are negative; staining with polyperoxidase/EMA antibody conjugate, and determining that melanoma is negative; 12C, the staining result of the polyperoxidase/GFAP antibody conjugate shows that melanoma is negative; staining with polyperoxidase/synapsin antibody conjugate, negative for melanoma; 12E, polyperoxidase/CD 45 antibody conjugate staining, melanoma is negative; 12 F.polyperoxidase/Mart 1 antibody conjugate staining, melanoma positive (cytoplasmic); polyperoxidase/Sox 10 antibody conjugate staining (cell nucleus) and positive melanoma; FIG. 12H, staining with polyperoxidase/CD 34 antibody conjugate, melanoma cells were negative.

Detailed Description

In order to solve the problems of non-specificity and low color difference inherent in the diagnosis of intraoperative oncology based on cryo-section hematoxylin and eosin staining, the present invention employs a rapid, sensitive and specific polymerase/antibody conjugate or combination thereof to shorten the time for immunohistochemical staining on fresh/frozen tissue. The polymer HRP-specific antibody conjugate which is specially designed and optimized can be directly combined with a specific antigen, a labeled secondary antibody in a two-step method is not needed, and various tumor cells with different colors can be displayed on fresh tissues or frozen sections within 10 minutes at room temperature. This novel 10-15 minute rapid immunohistochemical staining is useful for intraoperative cancer identification.

The current standard pathological diagnosis process is to perform immunohistochemical staining on paraffin-embedded tissue sections by using a combination of a polymerase-labeled secondary antibody and a set of antibodies for tumors such as brain tumors so as to achieve differential diagnosis. Since the staining process using this technique takes several hours to complete, it cannot be directly used for differential diagnosis of tumors in frozen tissue during surgery. The inventor establishes a set of polymerase/antibody conjugate combination containing a plurality of specific antibodies aiming at different antigens by using the polymerase/antibody conjugate technology, and the combination can carry out rapid immunohistochemical staining on tissue sections such as frozen sections within 10-15 minutes, thereby realizing rapid identification and diagnosis of tumors in surgery and immediately and accurately guiding the surgery.

The invention adopts polymerase-antibody covalent connection to form a conjugate. In one aspect, the invention provides a polymerase/antibody conjugate, wherein each polymerase/antibody conjugate comprises: (i) One or more polymerases, (ii) an antibody that recognizes a target analyte. In some embodiments, each polymerase has multiple enzyme molecules.

In some embodiments, the polymerase for use in the polymerase/antibody conjugates of the invention can include a plurality of enzyme molecules, for example, enzyme molecules including at least about 6 enzyme molecules, such as at least 8, at least 10, at least 12, at least 14, at least 16, at least 18, at least 20, at least 22, at least 24, at least 26, at least 28, at least 30, at least 32, at least 34, at least 36, at least 38, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 120, at least 140, at least 150, at least 160, at least 180, at least 200, at least 220, at least 240, about 250 enzyme molecules, or one or more of the above numbers. In some embodiments, a polymerase includes less than about 250, 200, 180, 160, 150, 140, 120, 100, 80, 75, 60, 50, 40, 25, 20, 15, or 10 enzyme molecules, or one or more of the above numbers of enzyme molecules. In some embodiments, the polymerase/antibody conjugates of the invention comprise between about 6 and about 80, between about 10 and about 80, between about 20 and about 80, between about 30 and about 80, between about 6 and about 100, between about 10 and about 100, between about 20 and about 100, between about 30 and about 100, between about 40 and about 100, between about 6 and about 200, between about 10 and about 200, between about 20 and about 200, between about 30 and about 200, between about 50 and about 200, between about 100 and about 200, between about 6 and about 250, between about 10 and about 250, between about 20 and about 250, between about 30 and about 250, between about 50 and about 250, between about 100 and about 250, or one or more of these numbers of enzyme molecules per polymerase/antibody conjugate.

In some embodiments, a polymerase/antibody conjugate of the invention comprises a plurality of polymerases, wherein each polymerase comprises about the same number of enzyme molecules. In some embodiments, a polymerase/antibody conjugate of the invention comprises a plurality of polymerases, wherein each polymerase comprises a different number of enzyme molecules. In some embodiments, a polymerase/antibody conjugate of the invention comprises a plurality of polymerases, wherein the plurality of polymerases exhibits a distribution of the number of enzyme molecules per polymerase. In some embodiments, the polymerase/antibody conjugate comprises a plurality of polymerases, wherein the plurality of polymerases have a random difference in shape.

In some embodiments, a polymerase/antibody conjugate of the invention can comprise a plurality of polymerases and antibodies, wherein each polymerase/antibody conjugate comprises a different number of enzyme molecules and antibodies, and the molecular weights of the conjugates form a polydisperse distribution. By polydisperse distribution is meant that the number of polymerase/antibody conjugates in each partition within the molecular weight range as defined above is not zero, and that the polydisperse distribution is characterized by a molecular weight of about 400kDa to about 2,000kda per polymerase/antibody conjugate. For example, between 400 and 600kDa, the number of which constitutes about 2 to 8%, e.g.4%, 5%, 6%, 7% or 8%, preferably 4% to 6%, of the total molecular weight range; between 600-800kDa about 5-10%, e.g. 6%, 7%, 8%, 9% or 10%, preferably 7-9%; 6-13%, e.g. 7%, 8%, 9%, 10%, 11% or 12%, preferably 9-11% between 800-1000 kDa; 7-14% between 1000-1200kDa, e.g. 8%, 9%, 10%, 11%, 12%, 13% or 14%, preferably 9-12%; 9-16% between 1200-1400kDa, e.g. 9%, 10%, 11%, 12%, 13%, 14%, 15% or 16%, preferably 11-13%; 10-16% between 1400-1600kDa, e.g. 10%, 11%, 12%, 13%, 14%, 15% or 16%, preferably 12-14%; between 1600 and 2000kDa 12-18%, e.g. 12%, 13%, 14%, 15%, 16%, 17% or 18%, preferably 13% -15%. Specifically, the polymerase/antibody conjugate of the invention may have a molecular weight of 300kDa to about 10,000kDa, preferably 400kDa to about 10,000kDa, 400kDa to about 5,000kDa, 500kDa to about 5,000kDa, or 750kDa to about 5,000kDa, with different molecular weights in each compartment within this range, and the molecular weight of the conjugate forms a polydisperse distribution as described above.

Immunohistochemistry is very different from antigen-antibody binding in liquids due to the complexity of the environment in which the antigens of biological tissues are located: the three-dimensional structure of tissue diversity and randomness forms a spatial network that blocks multiple and oversized polymerase/antibody conjugates. In order to make the polymerase/antibody conjugate access and combine with antigen rapidly and effectively, the scheme adopted by the invention is as follows: 1) Limiting the size of the polymerase/antibody conjugate; 2) Selecting polymerase/antibody conjugates with various molecular weights; 3) Three-dimensional structure of a diverse or random polymerase/antibody conjugate. Through repeated experiments, the invention adopts the polymerase/antibody conjugate with the molecular weight of the conjugate within the range of about 400kDa to about 2,000kDa and the molecular weight of the conjugate presenting random polydispersion distribution, namely the polymerase/antibody conjugate with different molecular weights and different three-dimensional structures in each interval within the range of 400kDa to about 2,000kDa, thereby realizing the rapid approach and the combination of a plurality of polymerase/antibody conjugates and corresponding antigens in frozen tissues. For example, between 400 and 600kDa, the number of which constitutes about 2 to 8%, e.g.4%, 5%, 6%, 7% or 8%, preferably 4% to 6%, of the total molecular weight range; between 600-800kDa about 5-10%, e.g. 6%, 7%, 8%, 9% or 10%, preferably 7-9%; 6-13%, e.g. 7%, 8%, 9%, 10%, 11% or 12%, preferably 9-11% between 800-1000 kDa; 7-14% between 1000-1200kDa, such as 8%, 9%, 10%, 11%, 12%, 13% or 14%, preferably 9% -12%; 9-16% between 1200-1400kDa, e.g. 9%, 10%, 11%, 12%, 13%, 14%, 15% or 16%, preferably 11-13%; 10-16% between 1400-1600kDa, e.g. 10%, 11%, 12%, 13%, 14%, 15% or 16%, preferably 12-14%; between 1600 and 2000kDa 12-18%, e.g. 12%, 13%, 14%, 15%, 16%, 17% or 18%, preferably 13-15%. And, for example, polymerase/antibody conjugates comprising randomly different three-dimensional structures within the interval of 400kDa to about 8,00kda; polymerase/antibody conjugates comprising another type of randomly different three-dimensional structure within the interval of 800kDa to about 1,200kda; polymerase/antibody conjugates comprising other types of random different three-dimensional structures within the interval of 1,200kda to about 1,600kda; other types of polymerase/antibody conjugates comprising randomly different three-dimensional structures are included in the interval of 1,600kda to about 2,000kda, wherein the three-dimensional structures of the polymerase/antibody conjugates in the above four intervals may be different.

The realization of the combined distribution is realized by the combination of the following variables; 1) Each polymerase/antibody conjugate consists of at least one polymerase; 2) The number of enzymes contained in each polymerase is one to several hundred; 3) The three-dimensional structure of the polymerase is various and random; 4) The binding site of the polymerase to the antibody is plural; 5) The manner in which each different polymerase binds to a different site of the antibody is random. These multiple variables are polydisperse in the distribution of molecular weights of the polymerase/antibody conjugate and diverse and random in their three-dimensional structure in the final product formed in the antibody/polymer conjugation reaction. The polymerase/antibody conjugate with the molecular weight distribution characteristics can be rapidly combined with the antigen in heterogeneous fresh or frozen section tissues, the incubation time is only 5 minutes or less to form a complex of the antigen and the polymerase/antibody conjugate, and the polymerase/antibody conjugate which does not form the complex is further removed by washing, so that the tissue-combined polymerase is contacted with a substrate of the polymerase, and the target analyte is rapidly detected.

In some embodiments, a polymerase/antibody conjugate of the invention can comprise a plurality of polymerases, each of which can comprise a different number of enzyme molecules, e.g., can comprise 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 50, 60, 70, 80, 90, 100, 120, 140, 150, 160, 180, 200, 220, 240, and/or 250 enzyme molecules, or one or more of the aforementioned numbers.

In some embodiments according to any of the embodiments described above, the molecular weight distribution of the polymerase/antibody conjugate of the invention is heterogeneous among molecular weight regions and its three-dimensional structure is diverse and random.

In some embodiments according to any of the embodiments described above, the polymerase/antibody conjugate of the invention may have a molecular weight between about 400kDa and about 500kDa, 600kDa, 700kDa, 800kDa, 900kDa, 1000kDa, 2000kDa, 3000kDa, 4000kDa, 5000kDa, 6000kDa, 7000kDa, 8000kDa, 9000kDa or l0000kDa, and/or a molecular weight between about 500kDa and about 600kDa, 700kDa, 800kDa, 900kDa, 1000kDa, 2000kDa, 3000kDa, 4000kDa, 5000kDa, 6000kDa, 7000kDa, 8000kDa, 9000kDa or l0000kDa, and/or a molecular weight between about 600kDa and about 700kDa, 800kDa, 900kDa, 1000kDa, 2000kDa, 3000, 4000kDa, 5000kDa, 6000, 7000kDa, 8000kDa, 9000kDa or l0000kDa, and/or has a molecular weight between about 700kDa and about 800kDa, 900kDa, 1000kDa, 2000kDa, 3000kDa, 4000kDa, 5000kDa, 6000kDa, 7000kDa, 8000kDa, 9000kDa or l0000kDa, and/or has a molecular weight between about 800kDa and about 900kDa, 1000kDa, 2000kDa, 3000kDa, 4000kDa, 5000kDa, 6000kDa, 7000kDa, 8000kDa, 9000kDa or l0000kDa, and/or has a molecular weight between about 900kDa and about 1000kDa, 2000kDa, 3000kDa, 4000kDa, 5000kDa, 6000kDa, 7000kDa, 8000kDa, 9000kDa or l0000kDa, and/or has a molecular weight between about 1000kDa and about 2000kDa, 3000kDa, 4000kDa, 5000kDa, 6000, 7000, 8000kDa, 9000kDa or l0000 kDa.

In some embodiments according to any of the embodiments above, a population of polymerases comprising a plurality of polymerases includes a size distribution of polymerases characterized by a number of enzyme molecules per polymerase. In some embodiments, a population of polymerases comprising a plurality of polymerases comprises a random distribution of polymerase shapes characterized by the structure of the polymerase. In a further embodiment, the distribution of molecular weights of a population of polymerases comprising a plurality of polymerases is heterogeneous and random. In some embodiments according to any of the above embodiments, the population of polymerases comprising a plurality of polymerases exhibits a random polydisperse distribution of molecular weights varying from about 2 to about 8%, e.g., 4%, 5%, 6%, 7%, or 8%, preferably 4% -6%, of the total molecular weight range between 400-600kDa, in each interval from 300kDa to about 5000 kDa; between 600-800kDa about 5-10%, e.g. 6%, 7%, 8%, 9% or 10%, preferably 7-9%; 6-13%, e.g. 7%, 8%, 9%, 10%, 11% or 12%, preferably 9-11% between 800-1000 kDa; 7-14% between 1000-1200kDa, such as 8%, 9%, 10%, 11%, 12%, 13% or 14%, preferably 9% -12%; 9-16% between 1200-1400kDa, e.g. 9%, 10%, 11%, 12%, 13%, 14%, 15% or 16%, preferably 11-13%; 10-16% between 1400-1600kDa, e.g. 10%, 11%, 12%, 13%, 14%, 15% or 16%, preferably 12-14%; between 1600 and 2000kDa 12-18%, e.g. 12%, 13%, 14%, 15%, 16%, 17% or 18%, preferably 13% -15%. More specifically, the polymerase/antibody conjugate of the invention may have a molecular weight of 300kDa to about 10,000kDa, preferably 400kDa to about 10,000kDa, 400kDa to about 5,000kDa, 500kDa to about 5,000kDa or 750kDa to about 5,000kDa, with different molecular weights in each interval within this range, and the molecular weight of the conjugate forming a polydisperse distribution as described above.

In some embodiments according to any of the embodiments described above, the polymerase/antibody conjugate of the invention comprises a plurality of enzyme molecules or polymerases, wherein the plurality of enzyme molecules or polymerases can comprise the same or different enzyme types, e.g., all enzyme molecules or polymerases in the polymerase/antibody conjugate of the invention can comprise horseradish peroxidase.

In some embodiments according to any of the embodiments described above, the polymerase/antibody conjugate of the present invention comprises a polymerase and an antibody, and the enzyme molecule of the polymerase may comprise horseradish peroxidase (HRP), β -D-galactosidase, alkaline phosphatase, superoxide dismutase, luciferase, lactate dehydrogenase, galactose oxidase, and the like.

In some embodiments according to any of the embodiments above, the polymerase/antibody conjugate of the invention can be formed by covalently linking a polymerase to an antibody.

In some embodiments according to any of the embodiments described above, the polymerase/antibody conjugate of the invention may comprise a primary antibody. In some embodiments, the primary antibody can comprise a full-length antibody, a monoclonal antibody, a polyclonal antibody, a chimeric antibody, a humanized antibody, a human antibody or antibody fusion protein, or an antigen-binding fragment.

Examples of antibody binding fragments include, but are not limited to, fab, F (ab ') 2, fab' fragments, fd fragments, single chain antibody molecules (e.g., scFv), fv fragments, diabodies, linear antibodies, and multispecific antibodies formed from antibody fragments.

In some embodiments according to any of the above embodiments, the antibody comprises IgG, igM, igE, igA, or IgD.

In some embodiments according to any of the embodiments above, the primary antibody may comprise or be selected from an antibody or antigen binding fragment that targets the antigen of interest of the invention and its associated disease, such as cancer. In further embodiments, the cancer comprises: brain tumors such as brain glioma, meningioma, medulloblastoma, ependymoma, schwannoma, intracranial neuroepithelial tumor, chordoma; epithelioid sarcoma; lymphoma; small cell carcinoma; a synovial tumor; neuroendocrine cell tumors, including olfactory cell tumors, medulloblastoma, neuroblastoma, pituitary adenoma; melanoma; lymphoma; metastatic tumors, and the like. In a further embodiment according to any of the embodiments above, the primary antibody or antigen binding fragment may comprise or be selected from the group consisting of: anti-Pan-CK, anti-GFAP, anti-EMA, anti-synaptoprotein (Synatophysin), anti-CD 34, anti-CD 45, anti-S-100, anti-NSE, anti-Vimentin (Vimentin), anti-LCA, anti-AFP, anti-CD 34, anti-Ki-67, anti-P63, anti-NFP, anti-IDH 1, anti-BRAF, anti-Chromogranin (Chromogranin), anti-LCA, anti-Mart-1, and anti-Sox-10 antibodies or antigen-binding fragments thereof.

In some embodiments according to any of the embodiments above, the polymerase/antibody conjugate of the invention comprises a polymerase molecule and an antibody, wherein the polymerase molecule can be covalently linked via a cross-linking agent. For example, the enzyme molecules of a polymerase can be covalently linked directly, or covalently linked in a linear fashion, or covalently linked in a branched fashion, or covalently linked in a mixed linear and branched fashion.

In another aspect of the invention, the invention provides a combination of polymerase/antibody conjugates comprising a plurality of polymerase/antibody conjugates of the invention as described above. In the combination of polymerase/antibody conjugates of the present invention, each of the plurality of polymerase/antibody conjugates may comprise: (i) One or more polymerases, (ii) an antibody that recognizes the analyte of interest.

In some embodiments according to any of the above embodiments, each polymerase/antibody conjugate in a polymerase/antibody conjugate combination of the invention may comprise a plurality of enzyme molecules, for example comprising at least about 6 enzyme molecules, such as at least 8, at least 10, at least 12, at least 14, at least 16, at least 18, at least 20, at least 22, at least 24, at least 26, at least 28, at least 30, at least 32, at least 34, at least 36, at least 38, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 120, at least 140, at least 150, at least 160, at least 180, at least 200, at least 220, at least 240, at least 250 enzyme molecules, or enzyme molecules of one or more of the above numbers. In some embodiments, a polymerase includes less than about 250, 200, 180, 160, 150, 140, 120, 100, 80, 75, 60, 50, 40, 25, 20, 15, or 10 enzyme molecules, or one or more of the aforementioned numbers of enzyme molecules. In some embodiments according to any of the above embodiments, the polymerase/antibody conjugate comprises between about 6 and about 80, between about 10 and about 80, between about 20 and about 80, between about 30 and about 80, between about 6 and about 100, between about 10 and about 100, between about 20 and about 100, between about 30 and about 100, between about 40 and about 100, between about 6 and about 200, between about 10 and about 200, between about 20 and about 200, between about 30 and about 200, between about 50 and about 200, between about 100 and about 200 enzyme molecules, between about 6 and about 250, between about 10 and about 250, between about 20 and about 250, between about 30 and about 250, between about 50 and about 250, between about 100 and about 250 enzyme molecules, or one or more of the above numbers of enzyme molecules per polymerase/antibody conjugate.

In some embodiments according to any of the above embodiments, each polymerase/antibody conjugate in the polymerase/antibody conjugate combinations of the invention comprises a plurality of polymerases and antibodies, wherein each polymerase comprises a different number of enzyme molecules, and the molecular weights of the conjugates form a polydisperse distribution characterized by a molecular weight of about 400kDa to about 2,000kda of each polymerase antibody conjugate. In one embodiment, the molecular weights of the polymerase/antibody conjugates in the polymerase/antibody conjugate combination of the present invention exhibit a random polydisperse distribution, i.e., there are polymerase/antibody conjugates of different molecular weights and different three-dimensional structures in each interval ranging from 400kDa to about 2,000kda. The polydisperse distribution means that the number of polymerase/antibody conjugates in each partition within the molecular weight range as defined above is not zero. For example, between 400 and 600kDa it accounts for about 2 to 8%, e.g.4%, 5%, 6%, 7% or 8%, preferably 4% to 6% of the total molecular weight range; between 600-800kDa about 5-10%, e.g. 6%, 7%, 8%, 9% or 10%, preferably 7-9%; 6-13%, e.g. 7%, 8%, 9%, 10%, 11% or 12%, preferably 9-11% between 800-1000 kDa; 7-14% between 1000-1200kDa, such as 8%, 9%, 10%, 11%, 12%, 13% or 14%, preferably 9% -12%; 9-16% between 1200-1400kDa, e.g. 9%, 10%, 11%, 12%, 13%, 14%, 15% or 16%, preferably 11-13%; 10-16% between 1400-1600kDa, e.g. 10%, 11%, 12%, 13%, 14%, 15% or 16%, preferably 12-14%; between 1600 and 2000kDa 12-18%, e.g. 12%, 13%, 14%, 15%, 16%, 17% or 18%, preferably 13% -15%. More specifically, the polymerase/antibody conjugate in the above combination of the invention may have a molecular weight of 300kDa to about 10,000kDa, preferably 400kDa to about 10,000kDa, 400kDa to about 5,000kDa, 500kDa to about 5,000kDa or 750kDa to about 5,000kDa, with different molecular weights in each interval within this range, and the molecular weights of the conjugate forming a polydisperse distribution as described above.

In some embodiments according to any of the embodiments above, each polymerase/antibody conjugate in a polymerase/antibody conjugate combination of the invention can contain a heterogeneous molecular weight of polymerases, and each polymerase can contain a different number of enzyme molecules, e.g., can contain 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 50, 60, 70, 80, 90, 100, 120, 140, 150, 160, 180, 200, 220, 240, and/or 250 enzyme molecules, or one or more of these numbers.

In some embodiments according to any of the embodiments described above, the distribution of molecular weight of each polymerase/antibody conjugate in the polymerase/antibody conjugate combination of the invention can be heterogeneous and random.

In some embodiments according to any of the embodiments described above, each polymerase/antibody conjugate in a combination of polymerase/antibody conjugates of the invention may have a molecular weight between about 400kDa to about 500kDa, 600kDa, 700kDa, 800kDa, 900kDa, 1000kDa, 2000kDa, 3000kDa, 4000kDa, 5000kDa, 6000kDa, 7000kDa, 8000kDa, 9000kDa or l0000kDa, and/or a molecular weight between about 500kDa to about 600kDa, 700kDa, 800kDa, 900kDa, 1000kDa, 2000kDa, 3000kDa, 4000kDa, 5000kDa, 6000kDa, 7000kDa, 8000kDa, 9000kDa or l0000kDa, and/or a molecular weight between about 600kDa to about 700kDa, 800, 900kDa, 1000, 2000, 3000kDa, 4000kDa, 5000kDa, 6000kDa, 7000kDa, 8000kDa, 9000kDa or l0000kDa, and/or has a molecular weight between about 700kDa and about 800kDa, 900kDa, 1000kDa, 2000kDa, 3000kDa, 4000kDa, 5000kDa, 6000kDa, 7000kDa, 8000kDa, 9000kDa or l0000kDa, and/or has a molecular weight between about 800kDa and about 900kDa, 1000kDa, 2000kDa, 3000kDa, 4000kDa, 5000kDa, 6000kDa, 7000kDa, 8000kDa, 9000kDa or l0000kDa, and/or has a molecular weight between about 900kDa and about 1000kDa, 2000kDa, 3000kDa, 4000kDa, 5000kDa, 6000kDa, 7000kDa, 8000kDa, 9000kDa or l0000kDa, and/or has a molecular weight between about 1000kDa and about 2000kDa, 3000kDa, 4000kDa, 5000kDa, 6000, 7000, 8000kDa, 9000kDa or l0000 kDa.

In some embodiments according to any of the embodiments described above, each polymerase/antibody conjugate in a polymerase/antibody conjugate combination of the invention can comprise a plurality of enzyme molecules or a plurality of polymerases, wherein the plurality of enzyme molecules or the plurality of polymerases can comprise the same enzyme type, e.g., all enzyme molecules or polymerases in a polymerase/antibody conjugate of the invention are horseradish peroxidase.

In some embodiments according to any of the embodiments described above, each polymerase/antibody conjugate in a polymerase/antibody conjugate combination of the invention can comprise multiple enzyme molecules or multiple polymerases, wherein the multiple enzyme molecules or multiple polymerases can comprise different enzyme types, e.g., some of the enzyme molecules or polymerases in a polymerase/antibody conjugate of the invention are horseradish peroxidase and others are alkaline phosphatase; or wherein the plurality of enzyme molecules or the plurality of polymerases can comprise the same enzyme class, e.g., the enzyme molecules or polymerases in the polymerase/antibody conjugates of the invention are each horseradish peroxidase.

In some embodiments according to any of the embodiments above, in the combination of polymerase/antibody conjugates of the invention, the polymerase may comprise or be selected from horseradish peroxidase, β -D-galactosidase, alkaline phosphatase, superoxide dismutase, luciferase, lactate dehydrogenase, galactose oxidase, and the like.

In some embodiments according to any of the above embodiments, each polymerase/antibody conjugate in the combination of polymerase/antibody conjugates of the invention comprises a primary antibody and a polymerase, wherein the primary antibody comprised by each polymerase/antibody conjugate may be an antibody directed against a different antigen. For example, a combination of polymerase/antibody conjugates of the invention comprises or is selected from two or more, such as three, four, five, six, seven or eight antibodies or antigen-binding fragments: anti-Pan-CK, anti-GFAP, anti-EMA, anti-synaptoprotein (Synatophysin), anti-CD 34, anti-CD 45, anti-Mart-1, and anti-Sox-10 antibodies or antigen-binding fragments thereof.

In some embodiments according to any of the embodiments above, each polymerase/antibody conjugate in the polymerase/antibody conjugate combination of the invention comprises a primary antibody, which may include or be selected from an antibody or antigen-binding fragment thereof targeting an antigen of interest of the invention and a disease associated therewith, such as cancer, and a polymerase. In further embodiments, the cancer comprises a brain tumor such as brain glioma, oligodendroglioma, IDH1 mutant tumor, astrocytoma, schwann cell tumor, choroid plexus neuroma, papillary tumor, spindle tumor, atypical teratoid/teratoid tumor, meningioma, ependymoma, schwann tumor, intracranial neuroepithelial tumor, chordoma; epithelioid sarcoma; lymphoma; small cell carcinoma; a synovial tumor; neuroendocrine cell tumors including olfactory cell tumors, medulloblastoma, neuroblastoma, pituitary adenoma; melanoma; lymphoma; metastatic tumors, and the like. In still further embodiments, the cancer is selected from brain tumors such as brain gliomas, oligodendrogliomas, IDH1 mutant tumors, astrocytomas, schwann cell tumors, choroid plexus neuromas, papillary tumors, spindle tumors, atypical teratoid/teratoid tumors, meningiomas, ependymomas, schwann tumors, intracranial neuroepithelial tumors, chordoma; epithelioid sarcoma; lymphoma; small cell carcinoma; a synovial tumor; neuroendocrine cell tumors including olfactory cell tumors, medulloblastoma, neuroblastoma, pituitary adenoma; melanoma; lymphoma; metastatic tumors, and the like. In a further embodiment according to any of the embodiments above, the primary antibody or antigen-binding fragment may comprise or be selected from two or more, such as three, four, five, six, seven or eight antibodies or antigen-binding fragments: anti-Pan-CK, anti-GFAP, anti-EMA, anti-synaptoprotein (Synatophysin), anti-CD 34, anti-CD 45, anti-Mart-1, and anti-Sox-10 antibodies or antigen-binding fragments thereof.

In some embodiments according to any of the above embodiments, in the combination of polymerase/antibody conjugates of the invention, each polymerase/antibody conjugate comprises a primary antibody and a polymerase, wherein the primary antibody may be an antibody directed against a different antigen. For example, a combination of polymerase/antibody conjugates of the invention may comprise or be selected from two or more antibodies or antigen-binding fragments of: anti-Pan-CK, anti-GFAP, anti-EMA, anti-synaptoprotein (Synatophysin), anti-CD 45, anti-S-100, anti-NSE, anti-vimentin, anti-LCA, anti-AFP, anti-CD 34, anti-Ki-67, anti-P63, anti-NFP, anti-IDH 1, anti-BRAF, anti-chromophagemin (Chromogranin), anti-LCA, anti-Mart-1, and anti-Sox-10 antibodies or antigen-binding fragments; preferably, six, seven or eight of the anti-Pan-CK, anti-GFAP, anti-EMA, anti-synaptophin (Synatophysin), anti-CD 34, anti-CD 45, anti-Mart-1 and anti-Sox-10 antibodies are included or selected.

In some embodiments according to any of the embodiments above, preferably, for example, the combination of a polymerase/antibody conjugate of the invention may comprise a polymerase/Mart-1 antibody conjugate and/or a polymerase/Sox-10 antibody conjugate and at least one (e.g. two, three, four, five, and six) polymerase/antibody conjugate selected from the group consisting of: a polymerase/Pan-CK antibody conjugate, a polymerase/GFAP antibody conjugate, a polymerase/EMA antibody conjugate, a polymerase/synaptophysin (Synatophysin) antibody conjugate, a polymerase/CD 34 antibody conjugate, and a polymerase/CD 45 antibody conjugate. For example, a combination of a polymerase/antibody conjugate of the invention may comprise or consist of a polymerase/Mart-1 antibody conjugate or a polymerase/Sox-10 antibody conjugate, a polymerase/GFAP antibody conjugate, a polymerase/Pan-CK antibody conjugate, and a polymerase/synaptoprotein antibody conjugate. Preferably, the combination of polymerase/antibody conjugates of the invention may comprise or consist of a polymerase/Mart-1 antibody conjugate or a polymerase/Sox-10 antibody conjugate, a polymerase/GFAP antibody conjugate, a polymerase/Pan-CK antibody conjugate, a polymerase/synapsin antibody conjugate, a polymerase/CD 45 antibody conjugate, and optionally a polymerase/EMA antibody conjugate, a polymerase/CD 34 antibody conjugate.

In some embodiments according to any of the above embodiments, in the combination of polymerase/antibody conjugates of the invention, each polymerase/antibody conjugate comprises a primary antibody and a polymerase, wherein the primary antibody or antigen-binding fragment thereof comprised by each polymerase/antibody conjugate is different. Preferably, the primary antibody comprises or is selected from one or more of anti-Pan-CK, anti-GFAP, anti-EMA, anti-synaptophin (synaptophysin), anti-CD 34, anti-CD 45, anti-Mart-1 and anti-Sox-10 antibodies or antigen-binding fragments, for example three, four, five, six, seven or eight of the above-mentioned antibodies.

In some embodiments according to any of the embodiments described above, the polymerase molecules used in the combination of polymerase/antibody conjugates of the invention can be covalently linked via a cross-linking agent. In some embodiments, the enzyme molecules of the polymerase can be directly covalently linked. In some embodiments, the enzyme molecules of the polymerase are covalently linked in a linear fashion. In some embodiments, the enzyme molecules of the polymerase are covalently linked in a branched fashion. In some embodiments, the enzyme molecules of the polymerase are covalently linked in a mixed linear and branched fashion.

In some embodiments according to any of the embodiments above, the polymerase population comprising a plurality of polymerases in the polymerase/antibody conjugate combination of the invention comprises a size distribution of polymerases characterized by the number of enzyme molecules per polymerase. In some embodiments, a population of polymerases comprising a plurality of polymerases comprises a shape distribution of polymerases characterized by a structure of the polymerases. The molecular weights of the polymerase/antibody conjugates form a polydisperse distribution, meaning that the number of polymerase/antibody conjugates in each partition within the molecular weight range as defined above is not zero. For example, between 400 and 600kDa, the number of which constitutes about 2 to 8%, e.g.4%, 5%, 6%, 7% or 8%, preferably 4% to 6%, of the total molecular weight range; between 600-800kDa about 5-10%, e.g. 6%, 7%, 8%, 9% or 10%, preferably 7-9%; 6-13%, e.g. 7%, 8%, 9%, 10%, 11% or 12%, preferably 9-11% between 800-1000 kDa; 7-14% between 1000-1200kDa, such as 8%, 9%, 10%, 11%, 12%, 13% or 14%, preferably 9% -12%; 9-16% between 1200-1400kDa, e.g. 9%, 10%, 11%, 12%, 13%, 14%, 15% or 16%, preferably 11-13%; 10-16% between 1400-1600kDa, e.g. 10%, 11%, 12%, 13%, 14%, 15% or 16%, preferably 12-14%; between 1600 and 2000kDa 12-18%, e.g. 12%, 13%, 14%, 15%, 16%, 17% or 18%, preferably 13% -15%. Preferably, the polymerase/antibody conjugates (e.g., as used in the examples) in the combination of exemplary polymerase/antibody conjugates of the invention have a molecular weight between 400 and 600kDa in an amount of about 4% to 6% of the total molecular weight range; between 600-800kDa and about 7% -9%; between 800-1000kDa and about 9% -11%; between 1000-1200kDa and about 10% -12%; between about 11% and 13% between 1200 and 1400 kDa; between 1400 and 1600kDa, about 12% -14%; between 1600 and 2000kDa, about 13% -15%. More specifically, the polymerase/antibody conjugate in the above combination of the invention may have a molecular weight of 300kDa to about 10,000kDa, preferably 400kDa to about 10,000kDa, 400kDa to about 5,000kDa, 500kDa to about 5,000kDa or 750kDa to about 5,000kDa, with different molecular weights in each interval within this range, and the molecular weights of the conjugate forming a polydisperse distribution as described above.

In some embodiments according to any of the above embodiments, the size distribution of the molecular weight of the population of polymerases comprising a plurality of polymerases in the polymerase/antibody conjugate combination of the invention is heterogeneous and random. In some embodiments according to any of the above embodiments, the population of polymerases comprising the plurality of polymerases exhibits a random polydisperse distribution of molecular weights varying between about 300kDa and about 5000 kDa. In some embodiments, the invention provides a combination of 6, 7 or 8 polyperoxidase/antibody conjugates formed by polyperoxidase with 6, 7 or 8 antibodies, respectively, associated with the identification of tumors, such as brain tumors, lymphomas, melanomas, metastatic cancers. These combinations of polymerase/antibody conjugates can be applied in the field related to tumors such as brain tumors, melanomas, and in particular can be used for the differential diagnosis of tumor brain tumors, melanomas and the determination of resection margins in surgery thanks to their rapid staining characteristics in fresh and frozen tissues. In a further embodiment, the intraoperative brain tumor combinations of the invention include a plurality (e.g., 4, 5, 6, 7, or 8) of polyperoxidase/antibody conjugates: polyperoxidase/Pan-CK antibody conjugate, polyperoxidase/GFAP antibody conjugate, polyperoxidase/EMA antibody conjugate, polyperoxidase/synapsin antibody conjugate, polyperoxidase/CD 45 antibody conjugate, polyperoxidase/CD 34 antibody conjugate, polyperoxidase/Mart-1 antibody conjugate and/or polyperoxidase/Sox-10 antibody conjugate. In a further embodiment, an exemplary intraoperative brain tumor combination of the invention consists of at least 6, 7 or 8 polyperoxidase/antibodies: polyperoxidase/Pan-CK antibody conjugates, polyperoxidase/GFAP antibody conjugates, polyperoxidase/EMA antibody conjugates, polyperoxidase/synapsin antibody conjugates, polyperoxidase/CD 45 antibody conjugates, polyperoxidase/CD 34 antibody conjugates, polyperoxidase/Mart-1 antibody conjugates, and/or polyperoxidase/Sox-10 antibody conjugates. The combination is designed specifically for the purpose of determining tumor grade and intraoperative differential diagnosis of metastatic, melanoma, glioma, meningioma, and medulloblastoma tumors.

Polyperoxidase-Pan-CKAntibody conjugate: squamous epithelium, glandular epithelium, and transitional cells from benign or malignant sources (e.g., small cell carcinoma, chordoma, synovium, and epithelioid sarcoma) are stained. In recent years, it has been used for the differential diagnosis of intracranial neuroepithelial tumors and metastatic cancers. In metastatic cancer cells, it stains cytoplasm in a positive diffusion mode with high diffusivity and relatively poor specificity.

Polyperoxidase-GFAPAntibody conjugate: staining was positive for normal, reactive and neoplastic astrocytes, ependymal cells and oligodendrocytes; ganglion cells, neurons, metastatic cancer of epithelial origin, fibroblasts and their sources stain negatively. The antibody was used to diagnose brain gliomas, and showed positive staining with diffuse cytoplasm. It shows focal staining negatives in metastatic cancers, lymphomas, medullary and other tumors of embryonic origin.

Polyperoxidase-EMAAntibody conjugate: EMA is present in various glandular epithelia such as breast, endocrine and apical secretory glands, and pancreas, while there is little or no EMA expression in gastrointestinal epithelium, endocervical epithelium, and prostate. EMA is positive in meningiomas, ependymomas (90% membrane response), schwannomas and chordomas.

Polyperoxidase/synapsin antibody conjugates: mainly used for identifying neuroendocrine cell tumors, including olfactory cell tumors, medulloblastoma, neuroblastoma, pituitary adenoma and small cell carcinoma. It stains negatively on gliomas and strongly positively on normal neurons and medulloblastomas. Combined with GFAP, pan-CK, they can be used for the differential diagnosis of medulloblastoma, metastatic cancer and glioma with primary neuron components, and are particularly suitable for the identification of medulloblastoma and metastatic cancer.

Polyperoxidase-CD45Antibody conjugate: for the identification of lymphomas. It stains negatively in gliomas and metastatic cancers.

Polyperoxidase-Mart-1 or Sox-10Antibody conjugate: for the identification of melanoma.

In a further embodiment according to any of the embodiments above, the use of a combination as described above wherein a portion of the polyperoxidase/antibody conjugate is also useful for pathological diagnosis in brain oncology, as shown in the examples. For example, polyperoxidase/Pan-CK antibody conjugate, polyperoxidase/GFAP antibody conjugate and polyperoxidase/CD 45 antibody conjugate are selected and applied to rapid diagnosis and identification of glioma, lymphoma, glioma or metastatic tumor in neurosurgery [8]. Table 1 summarizes the specific use of exemplary polyperoxidase/antibody conjugate combinations used in the examples of the present invention in oncology.

TABLE 1 differential use of combinations of exemplary polyperoxidase/antibody conjugates of the present invention in different tumor surgeries

+: positive; -: negative of

In another aspect of the present invention, the present invention provides a kit comprising the above-mentioned polymerase/antibody conjugate or polymerase/antibody conjugate combination of the present invention, said kit comprising a plurality of polymerase/antibody conjugates as described above or a combination of polymerase/antibody conjugates as described above, wherein each polymerase/antibody conjugate in said plurality of polymerase/antibody conjugates as described above or a combination of polymerase/antibody conjugates as described above may comprise a plurality of primary antibodies, preferably said plurality of primary antibodies may be directed against different antigens, such as different tumor antigens.

In a further embodiment according to any of the embodiments above, the plurality of primary antibodies may comprise or be selected from one or more, such as two, three, four, five, six, seven or eight antibodies or antigen-binding fragments: anti-Pan-CK, anti-GFAP, anti-EMA, anti-synaptoprotein (Synatophysin), anti-CD 34, anti-CD 45, anti-Mart-1, and anti-Sox-10 antibodies or antigen-binding fragments.

In a further embodiment according to any of the embodiments above, the kit of the invention comprises a) a polymerase/antibody conjugate, and b) instructions for use. In other embodiments, the kit comprises a) a polymerase/antibody conjugate, and b) a substrate for the polymerase. In a further embodiment, the kit of the invention comprises a) a polymerase/antibody conjugate, b) a substrate for the polymerase, and c) instructions for use. In some embodiments, the polymerase is a polymerized-HRP.

In a further embodiment according to any of the embodiments above, the kit comprises a) a combination of polymerase/antibody conjugates, and b) instructions for use. In some embodiments, the kit comprises a) a combination of a polymerase/antibody conjugate, and b) a substrate for the polymerase. In some embodiments, the kit comprises a) a combination of a polymerase/antibody conjugate, b) a substrate for the polymerase, and c) instructions for use. In some embodiments, the polymerase is a polymerized-HRP.

In yet another aspect of the invention, the invention provides a method for detecting a target analyte in a tissue, comprising:

contacting a tissue comprising a target analyte with a polymerase/antibody conjugate comprising a plurality of enzyme molecules and an antibody that recognizes the target analyte to form a complex comprising the target analyte and the polymerase/antibody conjugate; substantially removing the polymerase/antibody conjugate that does not form a complex; and contacting the tissue with a substrate for the plurality of enzyme molecules in the polymerase/antibody conjugate, thereby detecting the analyte of interest. In some embodiments, the tissue is frozen tissue.

In some embodiments, the present invention provides a method for detecting a target analyte in a tissue, comprising: (a) Contacting a tissue sample comprising a target analyte with a polymerase/antibody conjugate at an incubation temperature of between about 15 ℃ and about 45 ℃ for a time period of about 1 minute to about 1 hour to form a complex comprising the target analyte and at least one polymerase/antibody conjugate, wherein the antibody is capable of specifically binding to the target analyte; (b) Removing polymerase/antibody conjugates that do not form complexes; (c) Contacting the tissue sample with a substrate for the enzyme, thereby detecting the analyte of interest.

In some embodiments, a tissue sample (e.g., a tissue section) comprising a target analyte is contacted with a polymerase/antibody conjugate at an incubation temperature of between about 15 ℃ and about 45 ℃ for about 3 minutes to about 1 hour to form a complex comprising the target analyte and at least one polymerase/antibody conjugate, and the polymerase/antibody conjugate comprises a primary antibody capable of specifically binding to the target analyte. In the above embodiments, the tissue sample is a continuous frozen tissue section or a continuous paraffin section.

In a further embodiment according to any of the embodiments above, a tissue sample (e.g., a tissue section) comprising a series of analytes of interest (e.g., analyte a and analyte B) is contacted with a combination of polymerase/antibody conjugates (e.g., a polymerase/antibody conjugate that specifically binds to analyte a and a polymerase/antibody conjugate that specifically binds to analyte B) at an incubation temperature of about 15 ℃ and about 45 ℃ for about 3 minutes to about 1 hour to form a series of complexes comprising the analytes of interest and at least one polymerase/antibody conjugate, and the polymerase/antibody conjugates comprise primary antibodies capable of specifically binding to their respective analytes of interest. In some embodiments, the tissue sample is a continuous frozen tissue section or a continuous paraffin section.

In some embodiments according to any of the embodiments above, the incubation temperature is between about 15 ℃ and about 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44 or 45 ℃, between about 20 ℃ and about 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44 or 45 ℃, between about 25 ℃ and about 30 ℃, preferably between about 25 ℃ and about 37 ℃.

In some embodiments according to any of the above embodiments, the incubation time is between about 1 minute to about 3, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, or 60 minutes, between 5 minutes to about 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, or 60 minutes, between 10 minutes to about 15, 20, 25, 30, 35, 40, 45, 50, 55, or 60 minutes, between about 15 minutes to about 20, 25, 30, 35, 40, 45, 50, 55, or 60 minutes, between about 20 minutes to about 25, 30, 35, 40, 45, 50, 55, or 60 minutes, between about 25 minutes to about 30, 35, 40, 45, 50, 55, or 60 minutes, between about 30 minutes to about 35, 40, 45, 50, 55, or 60 minutes.

In more specific embodiments, the incubation time is about 1,2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, or 60 minutes.

Following incubation, the tissue samples are typically washed with a wash buffer, including, for example, PBS, TBS, MOPS, MES, HEPES, or bicarbonate buffer, optionally containing a detergent, such as tween 20 (e.g., 0.01-0.2% tween 20). For example, an exemplary wash buffer is 10mM PBS containing 0.05% tween 20.

The washing steps may be performed 2 to 6 times, preferably 3, 4 or 5 times, each washing step lasting 1,2, 3, 4, 5, 6, 7, 8, 9 or 10 minutes or more.

In some embodiments, the wash temperature is between about 15 ℃ and about 18, 19, 20, 21, 22, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 ℃, between about 20 ℃ and about 21, 22, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, or 45 ℃, between about 25 ℃ and about 30 ℃, or between about 25 ℃ and about 37 ℃.

In some embodiments, the washing temperature is about 15 ℃, 16 ℃, 17 ℃, 18 ℃, 19 ℃,20 ℃, 21 ℃, 22 ℃, 23 ℃, 24 ℃, 25 ℃, 26 ℃, 27 ℃, 28 ℃, 29 ℃, 30 ℃, 31 ℃, 32 ℃, 33 ℃, 34 ℃, 35 ℃, 36 ℃, 37 ℃, 38 ℃, 39 ℃,40 ℃, 41 ℃, 42 ℃, 43 ℃, 44 ℃ or 45 ℃.

In some embodiments, the wash time is between about 1 minute to about 3, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, or 60 minutes.

In some embodiments, the wash time is about 1,2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, or 60 minutes.

In some embodiments according to any of the above embodiments of the invention, the method further comprises a closing step comprising the steps of: contacting a tissue comprising a target analyte with a polymerase/antibody conjugate comprising a plurality of enzyme molecules and an antibody that recognizes the target analyte to form a complex comprising the target analyte and the polymerase/antibody conjugate; wherein the sealing step comprises contacting the tissue with a sealing agent.

In some embodiments, the method further comprises a blocking step comprising a blocking step prior to incubating the antibody conjugate with the tissue, wherein the blocking step comprises contacting the tissue with a blocking agent.

In some embodiments, the blocking agent comprises skim milk, BSA, casein, or animal serum.

In some embodiments, the blocking agent comprises a buffer, such as TBS or PBS, preferably TBS or PBS containing BSA.

In some embodiments, the blocking agent comprises a buffer system selected from PBS, TBS, MOPS, MES, HEPES, and bicarbonate, optionally containing serum albumin, e.g., 1-5% Bovine Serum Albumin (BSA), horse serum albumin, goat serum albumin, rabbit serum albumin, or gelatin, and tween 20, e.g., 0.001-0.05% tween 20.

In some embodiments, the sealant comprises about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10% skim milk.

In some embodiments, the blocking agent comprises about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, or 15% BSA.

In some embodiments, the blocking temperature is between about 15 ℃ and about 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, or 45 ℃, between about 20 ℃ and about 21, 22, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, or 45 ℃, between about 25 ℃ and about 30 ℃, preferably between about 25 ℃ and about 37 ℃.

In some embodiments, the blocking temperature is about 15 ℃, 16 ℃, 17 ℃, 18 ℃, 19 ℃,20 ℃, 21 ℃, 22 ℃, 23 ℃, 24 ℃, 25 ℃, 26 ℃, 27 ℃, 28 ℃, 29 ℃, 30 ℃, 31 ℃, 32 ℃, 33 ℃, 34 ℃, 35 ℃, 36 ℃, 37 ℃, 38 ℃, 39 ℃,40 ℃, 41 ℃, 42 ℃, 43 ℃, 44 ℃, or 45 ℃.

In some embodiments, the blocking time is between about 3 minutes and about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, or 60 minutes, between 5 minutes and about 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, or 60 minutes, between 10 minutes and about 15, 20, 25, 30, 35, 40, 45, 50, 55, or 60 minutes, between about 15 minutes and about 20, 25, 30, 35, 40, 45, 50, 55, or 60 minutes, between about 20 minutes and about 25, 30, 35, 40, 45, 50, 55, or 60 minutes, between about 25 minutes and about 30, 35, 40, 45, 50, 55, or 60 minutes, or between about 30 minutes and about 35, 40, 45, 55, or 60 minutes.

In some embodiments, the method further comprises a detection step. After the washing step, a detection agent comprising a substrate for the enzyme, e.g. DAB for HRP or fast red for AP, is added to the tissue sample.

In some embodiments, the detection reagent comprises a buffer, such as PBS or TBS buffer, optionally with BSA and/or polyethylene glycol.

In some embodiments according to any of the above embodiments of the invention, the enzymatic reaction is detected using a spectrophotometer. In some embodiments, the enzymatic reaction is detected using a chemo-photometer. In some embodiments, the enzymatic reaction is detected using a fluorescence detector. In some embodiments, the enzymatic reaction is detected using a colorimetric (colormetric) signal detector. In some embodiments, the enzymatic reaction is detected using light microscopy or fluorescence microscopy.

In some embodiments according to any of the above embodiments of the invention, the tissue is frozen tissue. In some embodiments, the tissue is paraffin embedded tissue. In some embodiments, the tissue sample is a clinical smear or cultured cell or tissue. Preferably, the tissue (sample) is a serial frozen tissue section or paraffin section.

In some embodiments, the tissue is a tissue section greater than about 5 μm thick. In some embodiments, the tissue is a tissue section about 5 μm thick. In some embodiments, the tissue is a tissue section less than about 5 μm thick. In some embodiments, the tissue is a tissue section from about 1.5 μm thick to about 5.5 μm thick. In some embodiments, the tissue is a tissue section from about 4.5 μm thick to about 7.5 μm thick.

In some embodiments, the method further comprises a fixation step. In some embodiments, the tissue is fixed in a fixative comprising an aldehyde. Preferably, the fixative comprising an aldehyde is formalin (formaldehyde) and glutaraldehyde, more preferably the fixative is 1-10% formalin. In another embodiment, the tissue is fixed in an acetone fixative. In another embodiment, the tissue is fixed in a methanol fixative. In another embodiment, the tissue is fixed in 50-90% alcohol fixative.

The invention has the advantages that:

treatment of primary tumors (e.g., brain tumors) typically involves surgical removal of the tumor. However, the thorough surgical removal of tumors (e.g., brain tumors) is very difficult due to tumor infiltration adjacent to delicate brain tissue, in part because the accuracy of tumor diagnosis, such as brain tumor, is not sufficient to evaluate intraoperative tumors by hematoxylin and eosin staining of frozen sectioned tissue. The invention adopts polymerase/antibody covalent connection to form a conjugate, synthesizes antibodies related to 5-8 tumors (such as brain tumor, lymphoma, melanoma and metastatic cancer) by polymerase respectively, forms a combination of 5-8 polymerase/antibody conjugates, is applied to the field related to tumor (such as brain tumor, lymphoma, melanoma and metastatic cancer) identification, particularly can be used for differential diagnosis of tumors (such as brain tumor, lymphoma, melanoma and metastatic cancer) in operation and determination of excision margin by virtue of the characteristic of rapid staining of fresh and frozen tissues, and improves the accuracy of tumor diagnosis. The application of this technique will be a significant improvement in surgical management, especially for certain invasive and aggressive brain cancers.

The specific technical scheme of the application is as follows.

1. A combination of polymerase/antibody conjugates comprising or selected from two, three, four or more of the following polymerase/antibody conjugates: a polymerase/Pan-CK antibody conjugate, a polymerase/EMA antibody conjugate, a polymerase/CD 34 antibody conjugate, a polymerase/synapsin antibody conjugate, a polymerase/Mart-1 antibody conjugate, a polymerase/Sox-10 antibody conjugate, a polymerase/GFAP antibody conjugate, and a polymerase/CD 45 antibody conjugate,

wherein each polymerase/antibody conjugate comprises:

(i) One or more polymerases;

(ii) At least one antibody recognizing an analyte of interest, wherein each polymerase has a plurality of enzyme molecules, wherein each polymerase/antibody conjugate comprises a different number of enzymes and antibodies, the molecular weights forming a polydisperse distribution, wherein the polymerase/antibody conjugates have different molecular weights and different three-dimensional structures in the respective regions ranging from 400kDa to 2,000kda, wherein the polymerase/antibody conjugates range from 2% to 8% by number in the entire molecular weight range between 400kDa and 600kDa, from 5% to 10% by number between 600kDa and 800kDa, from 6% to 13% by number between 800kDa and 1000kDa, from 7% to 14% by number between 1000kDa and 1200kDa, from 9% to 16% by number between 1200kDa and 10% to 18% by number between 1400kDa and 1600kDa, and from 12% to 18% by number between 1600kDa and 2000 kDa.

2. The combination of polymerase/antibody conjugates according to scheme 1, comprising, or consisting of, a polymerase antibody conjugate: a polymerase/GFAP antibody conjugate, a polymerase/Pan-CK antibody conjugate, a polymerase/EMA antibody conjugate and/or a polymerase/CD 34 antibody conjugate, and a polymerase/synaptoprotein antibody conjugate.

3. The combination of polymerase/antibody conjugates according to scheme 1, comprising a polymerase/Mart-1 antibody conjugate and/or a polymerase/Sox-10 antibody conjugate, and at least one polymerase antibody conjugate selected from the group consisting of: a polymerase/GFAP antibody conjugate, a polymerase/Pan-CK antibody conjugate, and a polymerase/synapsin antibody conjugate, or a combination thereof.

4. The combination of polymerase/antibody conjugates according to scheme 1, comprising a polymerase/Mart-1 antibody conjugate and/or a polymerase/Sox-10 antibody conjugate, and at least one polymerase antibody conjugate selected from the group consisting of: a polymerase/GFAP antibody conjugate, a polymerase/Pan-CK antibody conjugate, a polymerase/CD 45 antibody conjugate, a polymerase/synapsin antibody conjugate, a polymerase/EMA antibody conjugate, and a polymerase/CD 34 antibody conjugate.

5. The combination of polymerase/antibody conjugates according to scheme 1, comprising a polymerase/EMA antibody conjugate and/or a polymerase/CD 34 antibody conjugate, and at least one polymerase antibody conjugate selected from the group consisting of: polymerase/GFAP antibody conjugate, polymerase/Pan-CK antibody conjugate, polymerase/synapsin antibody conjugate and polymerase/CD 45 antibody conjugate.

6. The combination of polymerase/antibody conjugates according to scheme 1, comprising, or consisting of, a polymerase antibody conjugate: a polymerase/Pan-CK antibody conjugate, a polymerase/EMA antibody conjugate, or a polymerase/CD 34 antibody conjugate, a polymerase/synapsin antibody conjugate, a polymerase/Mart-1 antibody conjugate, or a polymerase/Sox-10 antibody conjugate, a polymerase/GFAP antibody conjugate, and a polymerase/CD 45 antibody conjugate.

7. The combination of polymerase/antibody conjugates of scheme 1, consisting of a polymerase/Pan-CK antibody conjugate, a polymerase/EMA antibody conjugate, a polymerase/CD 34 antibody conjugate, a polymerase/synapsin antibody conjugate, a polymerase/Mart-1 antibody conjugate, a polymerase/Sox-10 antibody conjugate, a polymerase/GFAP antibody conjugate, and a polymerase/CD 45 antibody conjugate.

8. The polymerase/antibody conjugate combination according to any of protocols 1-7, wherein the polymerase is selected from horseradish peroxidase (HRP), beta-D-galactosidase, alkaline phosphatase, superoxide dismutase, luciferase, lactate dehydrogenase, galactose oxidase.

9. A kit, comprising: a polymerase/antibody conjugate combination according to any of schemes 1-8 above, and instructions for use.

10. The kit according to scheme 9 above, further comprising a substrate for a polymerase molecule.

11. Use of a combination of polymerase/antibody conjugates according to any of the above schemes 1-8 in the preparation of a reagent or combination of reagents or kit for the identification and/or diagnosis of melanoma in a tissue sample.

12. The use of protocol 11 above, wherein the tissue sample is a surgical sample.

13. The use according to claim 11 or 12 above, wherein the tissue sample comprises (serial) paraffin or frozen tissue sections.

14. The use according to any one of the above schemes 11-13, wherein the melanoma is malignant melanoma.

Examples

Hereinafter, the present invention will be described in more detail with reference to specific examples in which preferred exemplary polyperoxidase antibody conjugates of the present invention are used. The following examples and descriptions are for illustrative purposes only and are not to be construed as limiting the spirit of the present invention.

The experimental procedures used in the following examples are conventional unless otherwise specified. Materials, reagents and the like used in the following examples are all commercially available conventional reagents unless otherwise specified.

Example 1 pretreatment of frozen tissue on slides

The frozen tissue sections placed on the slides were fixed in a fixative solution of 10% formalin or low temperature acetone for 30 seconds. The slides were then washed with phosphate wash buffer (PBS) for about 20 seconds; if the tissue sections are rich in endogenous peroxidase, the sections are treated with about 4% hydrogen peroxide blocking solution (4% hydrogen peroxide in water) for 1 to 2 minutes, after which the slides are washed with water and wash buffer, respectively, for about 20 seconds.

Example 2 polyperoxidase/Pan-CK antibody conjugate staining

The polyperoxidase/Pan-CK antibody conjugate was diluted to an appropriate concentration (1-30. Mu.g/ml) and added to the frozen prostate cancer tissue sections pretreated as above, and reacted for 3 to 5 minutes. Sections were washed 3 times with phosphate wash buffer (PBS) for 20 seconds. Substrate general DAB staining solution (Vector Lab, SK-4100) was added and reacted for 3 minutes. Slides were washed with water for 10 seconds to 1 minute 3 times. Add 150. Mu.l of general hematoxylin solution (Sigma-Aldrich) for 20 seconds to 1 minute of staining. Water rinse for 15 seconds (or longer) 3 times. Add 150. Mu.l of universal sealer (Vector Lab) coverslip. The entire staining was completed within 10 minutes. The micrograph of the tissue staining is shown in FIG. 1: the conjugate polyperoxidase/Pan-CK antibody conjugate disclosed by the invention can be used for quickly staining prostate cancer cell paste on a frozen prostate cancer section within 10 minutes, and specifically staining the prostate cancer cell paste.

Example 3 polyperoxidase/GFAP antibody conjugate staining

The polyperoxidase/GFAP antibody conjugate was diluted to an appropriate concentration (1-30. Mu.g/ml) and added to the brain tumor cryosection pretreated as above, and reacted for 3 to 5 minutes. Sections were washed 3 times with phosphate wash buffer (PBS) for 20 seconds. Substrate general DAB staining solution (Vector Lab, SK-4100) was added and reacted for 3 minutes. Slides were washed with water for 10 seconds to 1 minute 3 times. Add 150. Mu.l of general hematoxylin solution (Sigma-Aldrich) for 20 seconds to 1 minute of staining. Water rinse for 15 seconds (or longer) 3 times. Add 150. Mu.l of universal sealer (Vector Lab) coverslip. The entire staining was completed within 10 minutes. The micrograph of the tissue staining is shown in FIG. 2: the polyperoxidase/GFAP antibody conjugate disclosed by the invention can be quickly stained on a brain tumor cryosection within 10 minutes, and the cytoplasm of a brain astrocyte is specifically stained.

Example 4 polyperoxidase/EMA antibody conjugate staining

The polyperoxidase/EMA conjugate was diluted to the appropriate concentration (1-30. Mu.g/ml) and added to the frozen kidney tissue sections pretreated as above, and reacted for 3 to 5 minutes. Sections were washed 3 times with phosphate wash buffer (PBS) for 20 seconds. A substrate general DAB staining solution (Vector Lab, SK-4100) was added and the reaction was continued for 3 minutes. Slides were washed with water for 10 seconds to 1 minute 3 times. Add 150. Mu.l of general hematoxylin solution (Sigma-Aldrich) for 20 seconds to 1 minute of staining. Water rinse for 15 seconds (or longer) 3 times. Add 150. Mu.l of universal sealer (Vector Lab) coverslip. The entire staining was completed within 10 minutes. The micrograph of the tissue staining is shown in FIG. 3: the polyperoxidase/EMA antibody conjugate of the present invention stains rapidly in frozen kidney tissue sections for 10 minutes, and the renal parenchymal cancer cell plasma is stained specifically.

Example 5 polyperoxidase/synapsin antibody conjugate staining

The polyperoxidase/synapsin antibody conjugate was diluted to an appropriate concentration (1-30. Mu.g/ml) and added to the frozen liver tissue sections pretreated as above, and reacted for 3 to 5 minutes. Sections were washed 3 times with phosphate wash buffer (PBS) for 20 seconds. Substrate general DAB staining solution (Vector Lab, SK-4100) was added and reacted for 3 minutes. Slides were washed with water for 10 seconds to 1 minute 3 times. Add 150. Mu.l of general hematoxylin solution (Sigma-Aldrich) for 20 seconds to 1 minute of staining. Rinsing with water for 15 seconds (or more) 3 times. Add 150. Mu.l of universal sealer (Vector Lab) coverslip. The entire staining was completed within 10 minutes. The micrograph of the tissue staining is shown in FIG. 4: the polyperoxidase/synapsin antibody conjugate disclosed by the invention can be quickly stained on a liver tissue frozen section within 10 minutes, and the neuroendocrine tumor cytoplasm can be specifically stained.

Example 6 polyperoxidase/CD 45 antibody conjugate staining

The polyperoxidase/CD 45 antibody conjugate was diluted to an appropriate concentration (1-30. Mu.g/ml) and added to the frozen tonsil tissue sections pretreated as above, and reacted for 3 to 5 minutes. Sections were washed 3 times with phosphate wash buffer (PBS) for 20 seconds. Substrate general DAB staining solution (Vector Lab, SK-4100) was added and reacted for 3 minutes. Slides were washed with water for 10 seconds to 1 minute 3 times. Add 150. Mu.l of general hematoxylin solution (Sigma-Aldrich) for 20 seconds to 1 minute of staining. Water rinse for 15 seconds (or longer) 3 times. Add 150. Mu.l of universal sealant (Vector Lab) coverslip. The entire staining was completed within 10 minutes. The micrograph of the tissue staining is shown in FIG. 5: the polyperoxidase/CD 45 antibody conjugates of the present invention stain rapidly on tonsil cryosections for 10 minutes, with the lymphocyte membranes specifically stained.

Example 7 polyperoxidase/Mart-1 antibody conjugate staining

The polyperoxidase/Mart 1 antibody conjugate was diluted to the appropriate concentration (1-30. Mu.g/ml) and added to melanoma frozen tissue sections pretreated as above for 3 to 5 minutes of reaction. Sections were washed 3 times with phosphate wash buffer (PBS) for 20 seconds. Substrate general DAB staining solution (Vector Lab, SK-4100) was added and reacted for 3 minutes. Slides were washed with water for 10 seconds to 1 minute 3 times. Add 150. Mu.l of general hematoxylin solution (Sigma-Aldrich) for 20 seconds to 1 minute of staining. Water rinse for 15 seconds (or longer) 3 times. Add 150. Mu.l of universal sealer (Vector Lab) coverslip. The entire staining time was completed within 10 minutes. The micrograph of the tissue staining is shown in FIG. 6: the polyperoxidase/Mart 1 antibody conjugates of the present invention stain rapidly on melanoma cryosections for 10 minutes, where the melanoma cytoplasm is specifically stained.

Example 8 polyperoxidase/Sox-10 antibody conjugate staining

The polyperoxidase/Sox-10 antibody conjugate was diluted to an appropriate concentration (1-30. Mu.g/ml) and added to the melanoma cryo-sections pretreated as above, and reacted for 3 to 5 minutes. Sections were washed 3 times with phosphate wash buffer (PBS) for 20 seconds. A substrate general DAB staining solution (Vector Lab, SK-4100) was added and the reaction was continued for 3 minutes. Slides were washed with water for 10 seconds to 1 minute 3 times. Add 150. Mu.l of general hematoxylin solution (Sigma-Aldrich) for 20 seconds to 1 minute of staining. Water rinse for 15 seconds (or longer) 3 times. Add 150. Mu.l of universal sealer (Vector Lab) coverslip. The entire staining was completed within 10 minutes. The micrograph of the tissue staining is shown in FIG. 7: the polyperoxidase/Sox 10 antibody conjugate of the present invention rapidly stains on melanoma frozen sections, wherein the nuclei of melanoma are specifically stained.

Example 9 staining of sequential frozen sections of Low-grade gliomas with a combination of exemplary polyperoxidase/antibody conjugates of the present invention

polyperoxidase/Pan-CK antibody conjugate, polyperoxidase/GFAP antibody conjugate, polyperoxidase/EMA antibody conjugate, polyperoxidase/synapsin antibody conjugate, polyperoxidase/CD 45 antibody conjugate, polyperoxidase/Mart 1 antibody conjugate and polyperoxidase/Sox-10 antibody conjugate are respectively diluted to appropriate concentration (1-30 micrograms/ml) and added to a series of frozen sections which are pretreated as above and are diagnosed as low-grade glioma by classical pathology, and the reactions are respectively carried out for 3-5 minutes. Each section was washed 3 times with phosphate wash buffer (PBS) for 20 seconds. A DAB staining solution (Vector Lab, SK-4100) was added to each section and reacted for 3 minutes. Slides were washed 3 times with water for 10 seconds to 1 minute, respectively. Each section was stained with 150. Mu.l of a universal hematoxylin solution (Sigma-Aldrich) for 20 seconds to 1 minute, and then washed with water for 15 seconds (or longer) 3 times. Each section was individually coverslipped with 150. Mu.l of a universal sealant (Vector Lab). The entire staining was completed within 10 minutes. Photomicrographs of tissue staining of a series of low-grade glioma cryosections are shown in FIGS. 8A-8G: 8A, a low-grade glioma is negative according to a staining result of the polyperoxidase/anti-Pan-CK antibody conjugate; 8B polyperoxidase/anti-GFAP antibody conjugate, the low-grade glioma is positive; 8C, dyeing and staining the polyperoxidase/anti-synapsin antibody conjugate, wherein the low-grade glioma is weakly positive; 8D, dyeing and staining the polyperoxidase/anti-EMA antibody conjugate, wherein the low-grade glioma is negative; 8E, a result of staining by the polyperoxidase/anti-CD 45 antibody conjugate shows that the low-grade glioma is negative; 8F, dyeing and staining the polyperoxidase/anti-Mart 1 antibody conjugate, wherein the low-grade glioma is negative; 8G, dyeing and staining the polyperoxidase/anti-Sox 10 antibody conjugate, wherein the low-grade glioma is negative; 8H.H and E staining control. From the above results, the diagnosis results of the combination of the exemplary polyperoxidase/antibody conjugate were consistent with those of the classical pathological diagnosis.

Example 10 staining of high-grade glioma with exemplary polyperoxidase/antibody conjugates of the present invention

polyperoxidase/Pan-CK antibody conjugate, polyperoxidase/GFAP antibody conjugate, polyperoxidase/EMA antibody conjugate, polyperoxidase/synapsin antibody conjugate, polyperoxidase/CD 45 antibody conjugate, polyperoxidase/Mart 1 antibody conjugate and polyperoxidase/Sox-10 antibody conjugate are respectively diluted to appropriate concentration (1-30 micrograms/ml) and added to a series of frozen sections which are pretreated as above and are diagnosed as high-grade glioma by classical pathology, and the reaction is respectively carried out for 3-5 minutes. Each section was washed 3 times with phosphate wash buffer (PBS) for 20 seconds. A DAB staining solution (Vector Lab, SK-4100) was added to each section and reacted for 3 minutes. Slides were washed 3 times with water for 10 seconds to 1 minute, respectively. Each section was stained with 150. Mu.l of a universal hematoxylin solution (Sigma-Aldrich) for 20 seconds to 1 minute, and then washed with water for 15 seconds (or longer) 3 times. Each section was individually coverslipped with 150. Mu.l of a universal sealant (Vector Lab). The entire staining was completed within 10 minutes. Photomicrographs of tissue staining of a series of high grade glioma cryosections are shown in FIGS. 9A-9G: 9A, a polyperoxidase/Pan-CK antibody conjugate staining result shows that high-grade glioma is negative; 9B polyperoxidase/anti-GFAP antibody conjugate staining result, high-grade glioma is positive; 9C, dyeing and staining the polyperoxidase/EMA antibody conjugate, wherein the high-grade glioma is negative; 9D, the polyperoxidase/synapsin antibody conjugate is dyed and dyed, and the high-grade glioma is negative; 9E, the result of the staining of the polyperoxidase/CD 45 antibody conjugate shows that the high-grade glioma is negative; 9F, dyeing and staining the polyperoxidase/Mart 1 antibody conjugate, wherein the high-grade glioma is negative; 9G, the polyperoxidase/Sox 10 antibody conjugate is dyed and dyed, and the high-grade glioma is negative; 9H & E staining control. From the above results, the diagnosis results of the combination of the exemplary polyperoxidase/antibody conjugates of the present invention are consistent with the results of classical pathological diagnosis.

Example 11 staining of serial frozen sections of metastatic carcinoma with exemplary polyperoxidase/antibody conjugates of the present invention

The polyperoxidase/Pan-CK antibody conjugate, polyperoxidase/GFAP antibody conjugate, polyperoxidase/EMA antibody conjugate, polyperoxidase/synapsin antibody conjugate, polyperoxidase/CD 45 antibody conjugate, polyperoxidase/Mart 1 antibody conjugate, polyperoxidase/Sox-10 antibody conjugate, respectively, were diluted to an appropriate concentration (1-30. Mu.g/ml) and added to a series of frozen sections, which were pretreated as above and diagnosed with metastatic cancer by classical pathology, and reacted for 3-5 minutes, respectively. Each section was washed 3 times with phosphate wash buffer (PBS) for 20 seconds. A DAB staining solution (Vector Lab, SK-4100) was added to each section and reacted for 3 minutes. Slides were washed 3 times with water for 10 seconds to 1 minute, respectively. Each section was stained with 150. Mu.l of a universal hematoxylin solution (Sigma-Aldrich) for 20 seconds to 1 minute, and then washed with water for 15 seconds (or longer) 3 times. Each section was individually coverslipped with 150. Mu.l of a universal sealant (Vector Lab). The entire staining was completed within 10 minutes. A series of photomicrographs of tissue staining of frozen sections of metastatic cancer are shown in figures 10A-10G: 10A, staining by a polyperoxidase/Pan-CK antibody conjugate, and enabling metastatic cancer cells to be positive; 10B, dyeing by using a polyperoxidase/EMA antibody conjugate, and determining that metastatic cancer is weakly positive; 10C, the result of the polyperoxidase/anti-GFAP antibody conjugate dyeing shows that the metastatic cancer is negative; polyperoxidase/synapsin antibody conjugate staining, and the metastatic cancer is negative; 10E, polyperoxidase/CD 45 antibody conjugate staining, and the metastatic cancer is negative; 10F, dyeing the polyperoxidase/Mart 1 antibody conjugate, wherein the metastatic cancer is negative; 10G, dyeing by using the polyperoxidase/Sox 10 antibody conjugate, wherein the metastatic cancer is negative; 10H.H &E staining control. From the above results, the diagnosis results of the combination of the exemplary polyperoxidase/antibody conjugate are consistent with the results of classical pathological diagnosis.

Example 12 staining of melanoma in serial frozen sections with exemplary polyperoxidase/antibody conjugates of the present invention

polyperoxidase/Pan-CK antibody conjugate, polyperoxidase/GFAP antibody conjugate, polyperoxidase/EMA antibody conjugate, polyperoxidase/synapsin antibody conjugate, polyperoxidase/CD 45 antibody conjugate, polyperoxidase/Mart 1 antibody conjugate, polyperoxidase/Sox-10 antibody conjugate, respectively, were diluted to appropriate concentrations (1-30. Mu.g/ml) and added to a series of frozen sections pre-treated as above, which were diagnosed with malignant melanoma by classical pathology, for 3 to 5 minutes, respectively. Each section was washed 3 times with phosphate wash buffer (PBS) for 20 seconds. A DAB staining solution (Vector Lab, SK-4100) was added to each section and reacted for 3 minutes. Slides were washed 3 times with water for 10 seconds to 1 minute, respectively. Each section was stained with 150. Mu.l of a universal hematoxylin solution (Sigma-Aldrich) for 20 seconds to 1 minute, and then washed with water for 15 seconds (or longer) 3 times. Each section was individually coverslipped with 150. Mu.l of a universal sealant (Vector Lab). The entire staining was completed within 10 minutes. The results are shown in fig. 11A to 11H, showing that both polyperoxidase/Mart 1 antibody conjugate and polyperoxidase/Sox-10 antibody conjugate stained malignant melanoma positively, and that each of the other polyperoxidase/antibody conjugates stained melanoma negatively, indicating that the diagnostic results for the combination of the exemplary polyperoxidase/antibody conjugates are consistent with the classical pathological diagnostic results.

Example 13 staining of melanoma in serial paraffin sections with exemplary polyperoxidase/antibody conjugates of the present invention

polyperoxidase/Pan-CK antibody conjugate, polyperoxidase/GFAP antibody conjugate, polyperoxidase/EMA antibody conjugate, polyperoxidase/synapsin antibody conjugate, polyperoxidase/CD 45 antibody conjugate, polyperoxidase/Mart 1 antibody conjugate and polyperoxidase/Sox-10 antibody conjugate are respectively diluted to appropriate concentration (1-30 micrograms/ml) and added to a series of paraffin sections which are diagnosed as malignant melanoma by classical pathology and are subjected to conventional dewaxing treatment and antigen retrieval, and the reaction is respectively carried out for 3-10 minutes. Each section was washed 3 times with phosphate wash buffer (PBS) for 20 seconds. A DAB staining solution (Vector Lab, SK-4100) was added to each section and reacted for 3 minutes. Slides were washed 3 times with water for 10 seconds to 1 minute, respectively. Each section was stained with 150. Mu.l of a universal hematoxylin solution (Sigma-Aldrich) for 20 seconds to 1 minute, and then washed with water for 15 seconds (or longer) 3 times. Each section was individually coverslipped with 150. Mu.l of a universal sealant (Vector Lab). The entire staining was completed in 10 to 20 minutes. The results are shown in fig. 12A to 12H, showing that except the polyperoxidase/Mart 1 antibody conjugate and the polyperoxidase/Sox-10 antibody conjugate stained positive for malignant melanoma, each of the polyperoxidase/antibody conjugates stained negative for melanoma, indicating that the diagnostic results of the combination of the exemplary polyperoxidase/antibody conjugates are consistent with the classical pathological diagnostic results.

The above combination of antibodies is merely exemplary, and in addition, it can be coupled with other polymerases, and different colors can be applied to the same tissue section by using different color reaction substrates, so as to perform the related identification and localization of tumors.

Document index

[1]Timothy J.Brown,Matthew C.Brennan,Michael Li,Association of the Extent of Resection with Survivalin Glioblastoma A Systematic Review and Meta-analysis,JAMA Oncol.2016；2(11):1460-1469

[2]Daniel A Orringer,Alexandra Golbyand Ferenc Jolesz,Neuronavigation in the surgical management of brain tumors:currentandfuture trends,ExpertRevMed Devices.2012Sep； 9(5):491–500.

[3]Richard A.Prayson,Mark L.Cohen,Differential Diagnosis in Surgical Neuropathology, Humana Press,May 19,2010.

[4]Todd Hollon,Spencer Lewis,Christian W.Freudiger,X.SunneyXie,and Daniel A.Orringer,Improving the accuracy of brain tumor surgery via Raman-based technology Neurosurg Focus 40(3):E9,2016

[5]Edward R.St Johna,Merja Rossib,Pamela Pruskib,Ara Darzia,Zoltan Takats: Intraoperative tissue identification by mass spectrometric technologies,TrAC Trendsin Analytical Chemistry,Volume85,PartA,2016,On-site and In-vivo Instrumentation and Applications.

[6]Jennifer eschbacher,Nikolayl.Martirosyan,Peternaka Ji,NaDer Sanai,Mark C.Preul, KrisA.Smith,Stephen W.Coons,and Robert F.Spetzler:In vivo intraoperative confocal microscopy forreal-time histopathological imaging of brain tumors.J NeurosurgVolume 116,2012

[7]Young Jin Cho:Intraoperative Examination of Sentinel Lymph Nodes by Ultrarapid Immunohistochemistry in Breast Cancer,Jpn J Clin Oncol 2006；36(8)489-493.

[8]Xuebin Zhang,Jiayu Liu,Xiaoling Yan,Rapid intraoperative immunocytochemistry of central nervous system tumors,Int J Clin Exp Pathol.2020；13(1):44-48。

Claims

1. A combination of polymerase/antibody conjugates comprising or selected from two or more of the following polymerase/antibody conjugates: a polymerase/Pan-CK antibody conjugate, a polymerase/EMA antibody conjugate, a polymerase/CD 34 antibody conjugate, a polymerase/synapsin antibody conjugate, a polymerase/Mart-1 antibody conjugate, a polymerase/Sox-10 antibody conjugate, a polymerase/GFAP antibody conjugate, and a polymerase/CD 45 antibody conjugate,

wherein each polymerase/antibody conjugate comprises:

(i) One or more polymerases;

2. The polymerase/antibody conjugate combination of claim 1, comprising a polymerase/Mart-1 antibody conjugate and/or a polymerase/Sox-10 antibody conjugate, and at least one polymerase antibody conjugate selected from the group consisting of: a polymerase/GFAP antibody conjugate, a polymerase/Pan-CK antibody conjugate, a polymerase/CD 45 antibody conjugate, a polymerase/synapsin antibody conjugate, a polymerase/EMA antibody conjugate, and a polymerase/CD 34 antibody conjugate.

3. The polymerase/antibody conjugate combination of claim 2, comprising a polymerase/Mart-1 antibody conjugate and/or a polymerase/Sox-10 antibody conjugate, and at least one polymerase antibody conjugate selected from the group consisting of: polymerase/GFAP antibody conjugates, polymerase/Pan-CK antibody conjugates, and polymerase/synaptoprotein antibody conjugates.

4. The polymerase/antibody conjugate combination of claim 1, comprising, or consisting of, a polymerase antibody conjugate: a polymerase/Pan-CK antibody conjugate, a polymerase/EMA antibody conjugate, or a polymerase/CD 34 antibody conjugate, a polymerase/synapsin antibody conjugate, a polymerase/Mart-1 antibody conjugate, or a polymerase/Sox-10 antibody conjugate, a polymerase/GFAP antibody conjugate, and a polymerase/CD 45 antibody conjugate.

5. The combination of polymerase/antibody conjugates of claim 1, consisting of a polymerase/Pan-CK antibody conjugate, a polymerase/EMA antibody conjugate, a polymerase/CD 34 antibody conjugate, a polymerase/synapsin antibody conjugate, a polymerase/Mart-1 antibody conjugate, a polymerase/Sox-10 antibody conjugate, a polymerase/GFAP antibody conjugate, and a polymerase/CD 45 antibody conjugate.

6. The polymerase/antibody conjugate combination of any of claims 1-5, wherein the polymerase is selected from horseradish peroxidase (HRP), beta-D-galactosidase, alkaline phosphatase, superoxide dismutase, luciferase, lactate dehydrogenase, galactose oxidase.

7. A kit, comprising: the polymerase/antibody conjugate combination of any of claims 1-6, and instructions for use.

8. The kit of claim 7, further comprising a substrate for a polymerase molecule.

9. Use of a combination of polymerase/antibody conjugates according to any of claims 1-8 for the preparation of a reagent or a combination of reagents or a kit for the identification and/or diagnosis of melanoma in a tissue sample.

10. The use of claim 9, wherein the tissue sample is a surgical sample.

11. Use according to claim 9 or 10, wherein the tissue sample comprises (serial) paraffin or frozen tissue sections.

12. The use according to any one of claims 9-11, wherein the melanoma is malignant melanoma.